Podcasts about massachusetts medical center

In today's episode I speak with workplace ally Karen Catlin and emergency medicine physician toxicologist Kavita Babu. We discuss Karen's book Belonging in Healthcare. We also highlight what belonging in the workplace can mean at the holidays. For 25 years Karen Catlin built software products and served as a vice president of engineering at Macromedia and Adobe, Today, she is a highly acclaimed author and speaker on inclusive workplaces. She is the author of five books: Better Allies: Everyday Actions to Create Inclusive, Engaging Workplaces, Belonging in Healthcare, The Better Allies Approach to Hiring, Present! A Techie's Guide to Public Speaking, and The Better Allies Way.  ​​Kavita Babu, MD is a Professor of Emergency Medicine Chief Opioid Officer, and Director, Division of Toxicology at the University of Massachusetts Medical Center. She is a graduate of Warren Alpert School of Medicine of Brown University where she also did her residency, followed by her Medical Toxicology Fellowship training at the UMass Chan Medical School.  

A growing discipline, palliative care medicine remains underutilized. Studies suggest that patients and providers commonly confuse palliative care with end-of-life care. In this episode, Dr. Liu is joined by Dr. Sunita Puri, Program Director of the Hospice and Palliative Medicine Fellowship at the University of Massachusetts Medical Center & Chan School of Medicine and author of That Good Night: Life and Medicine in the Eleventh Hour. During their discussion, Dr. Puri explains how fears related to misconceptions about palliative care can rob patients of their opportunity to engage in important conversations about living with chronic disease. As in her book, Dr. Puri uses stories to illustrate that palliative medicine moves its focus away from cures – focusing instead on questions regarding quality of life - about symptom management, hope, and what a ‘miracle' might really mean. About our Guest, Sunita Puri, M.D. Dr. Sunita Puri is the Program Director of the Hospice and Palliative Medicine Fellowship at the University of Massachusetts Medical Center & Chan School of Medicine, where she is also an associate professor of clinical medicine. A graduate of Yale University, she completed medical school and residency training in internal medicine at the University of California San Francisco followed by fellowship training in palliative medicine at Stanford. She is the author of That Good Night: Life and Medicine in the Eleventh Hour, a critically acclaimed literary memoir examining her journey to the practice of palliative medicine, and her quest to help patients and families redefine what it means to live and die well in the face of serious illness. She is the recipient of a Rhodes Scholarship and a Paul and Daisy Soros Fellowship for New Americans. Her writing and book have been featured in the New York Times, the Los Angeles Times, Slate, JAMA, the Atlantic, NPR, India Today, the Asian Age, the Oncology Times, and, forthcoming, the New Yorker. In 2019, the Guardian made a mini-documentary of her work in palliative medicine which has been viewed nearly 3 million times. She has been interviewed on the PBS Cristian Amanpour show, at the Commonwealth Club in San Francisco, ZDogg MD's show, and numerous podcasts. In 2018, she was awarded the Etz Chaim Tree of Life Award from the USC School of Medicine, awarded annually to a member of the faculty who, in the eyes of the campus community, models and provides humanistic and compassionate care. She has taught medical memoir and literary nonfiction to medical students and residents, and has delivered talks about palliative medicine, the centrality of narrative and storytelling in medicine, and physician well-being in forums around the world. ABOUT THE BOOK Interweaving evocative stories of Puri's family and the patients she cares for, That Good Night is a stunning meditation on impermanence and the role of medicine in helping us to live and die well, arming readers with information that will transform how we communicate with our doctors about what matters most to us. --- Support this podcast: https://podcasters.spotify.com/pod/show/aimatmelanoma/support

On today's episode of Ask Dr Jessica, we discuss the topic of scoliosis.   Today's guest is Dr Michael Heffernan, pediatric spine surgeon who works at Children's hospital of Los Angeles. In this episode we talk about everything you've ever wondered about scoliosis--like, what is scoliosis exactly? is it preventable? if a child is diagnosed with scoliosis, what can be done about it?   If a child has scoliosis, will it lead to back pain? When is bracing indicated? If a child is recommended to receive surgery, what will that process and recovery look like? We discuss all of this about scoliosis and more!Michael Heffernan, MD, is a Board-certified orthopedic surgeon who specializes in the surgical and nonsurgical management of scoliosis and other pediatric spinal conditions. He is an Associate Professor of Clinical Orthopedic Surgery at the Keck School of Medicine of USC.  He can be reached by his email Dr Heffernan's email: mheffernan@chla.usc.edu and he can be found on his instagram @Before joining the Spine Program at Children's Hospital Los Angeles, Dr. Heffernan served as the Director of the Pediatric Orthopedic & Spine Deformity Fellowship at Children's Hospital New Orleans. Dr. Heffernan is active in the Pediatric Orthopaedic Society of North America, the Scoliosis Research Society and the Pediatric Spine Study Group. He is passionate about global outreach and is Chair of the Global Outreach Committee for the Pediatric Orthopaedic Society of North America. He has also served on the Scoliosis Research Society's global outreach committee and works with surgeons at Kingston Public Hospital to advance the care of children with scoliosis in Kingston, Jamaica.After receiving his undergraduate degree at the Pennsylvania State University, Dr. Heffernan received his medical degree from the University of Pittsburgh School of Medicine. He went on to an orthopedic surgery residency at the University of Massachusetts Medical Center. Dr. Heffernan then completed his advanced fellowship training in pediatric orthopedics and pediatric spinal deformity at Children's Hospital Los Angeles. When Dr. Heffernan is not working, he enjoys spending time outdoors with his wife, Joanne, and their two daughters, Sophie and Riley.He can be reached by his email: mheffernan@chla.usc.edu Andrew Chung, PA-C email: achung@chla.usc.eduCHLA phone number is: 323-361-4658ortho websiteGet matched with a therapist by using Better Help! Give it a try---invest in your mental health: https://betterhelp.com/askdrjessica for 10% off your first month of therapy. Thank you to Better Help for supporting the Ask Dr Jessica podcast.Dr Jessica Hochman is a board certified pediatrician, mom to three children, and she is very passionate about the health and well being of children. Most of her educational videos are targeted towards general pediatric topics and presented in an easy to understand manner. Do you have a future topic you'd like Dr Jessica Hochman to discuss? Email Dr Jessica Hochman askdrjessicamd@gmail.com. Dr Jessica Hochman is also on social media:Follow her on Instagram: @AskDrJessicaSubscribe to her YouTube channel! Ask Dr JessicaSubscribe to this podcast: Ask Dr JessicaSubscribe to her mailing list: www.askdrjessicamd.comThe information presented in Ask Dr Jessica is for general educational purposes only. She does not diagnose medical conditions or formulate treatment plans for specific individuals. If you have a concern about your child's health, be sure to call your child's health care provider.

Part 1 - Mindfulness in the Buddhist Path from 'What Does Mindfulness Really Mean' by Bhikkhu Bodhi . The entry of systematic mindfulness practice into the fields of stress reduction and psychotherapy has dramatically altered modern medicine's perspectives on our capacity to regulate and overcome our human vulnerabilities. Mindfulness made its debut as a therapeutic discipline in 1979, when Jon Kabat-Zinn introduced his program of “Mindfulness-Based Stress Reduction” at the University of Massachusetts Medical Center. Since then its use to reduce pain and stress has been adopted by hundreds of medical centers, hospitals, and clinics around the world. The application of mindfulness in clinical settings has spread beyond stress reduction to psychotherapy, where it has proven a potent tool for helping patients deal with such conditions as depression, anxiety, and obsessive-compulsive disorders. narrated by Jonathan Nelson 2023 12 minutes 20 seconds Listen to Streaming Audio Your browser does not support the audio element. Download Audio (6.1MB) Audio copyright, 2023 Pariyatti 'Investigating the Dhamma' as a book and eBook can be found at https://store.pariyatti.org/investigating-the-dhamma. More by Bhikkhu Bodhi. View more books and audio resources available in the Pariyatti bookstore.

...so let's spend just a few minutes explaining what mindfulness is, and what it isn't. Because in the past few decades, mindfulness has gained tremendous popularity as both a formal practice as well as a way of being, of living. And as with anything that gets mass marketed, some products out there are authentic, and some are knock offs. Mindfulness was initially introduced to the Western world and more specifically to the medical community, by Dr. Jon Kabbat-Zinn, a pain medicine physician at the University of Massachusetts Medical Center.

This episode of EMS One-Stop With Rob Lawrence is brought to you by Lexipol, the experts in policy, training, wellness support and grants assistance for first responders and government leaders. To learn more, visit lexipol.com. This week, Host Rob Lawrence welcomes back, Alexander Isakov, MD, MPH, professor of emergency medicine at Emory University School of Medicine, executive director of the Emory Office of Critical Event Preparedness and Response (CEPAR), and EMS lead for the National Emerging Special Pathogens Training and Education Center (NETEC). Returning guest, Dr. Isakov provides an update on the current emerging pathogens, diseases, outbreaks and fevers that have featured recently in the news. Candida auris, Marburg virus disease, avian influenza, Nipah virus are discussed as well as recaps on Ebola, COVID-19, polio and seasonal influenza. TOP QUOTES FROM THIS EPISODE “What's concerning CDC officials and experts is there is a multi-drug resistant strain of Candida auris that is really picking up in their surveillance programs.” “While no one wants to be exposed to a multi-drug-resistant Candida auris, it's really the ominous compromised patient that's going to be likely most affected by it, so that means elderly patients or patients that are getting chemotherapy and have some immunosuppression consequence of that or people that are taking immunosuppressant drugs, they are the ones really at greatest risk.” “The likelihood that EMS personnel are going to encounter somebody with Marburg virus disease in the U.S. during routine operations is extremely low, but good to be vigilant about it and identifying that someone might have been exposed, and understanding their travel history, if someone is ill, has a fever or myalgia, GI complaints and has travelled within the last 21 days to equatorial Guinea or Tanzania, then it would raise suspicion.” ADDITIONAL RESOURCES ON THIS TOPIC CDC: Infection prevention and control for Candida auris CDC: Information for infection preventionists NETEC: Situation report: Marburg cases rise in equatorial Guinea and Tanzania NETEC: EMS guidelines for Marburg virus disease ABOUT OUR GUEST Alexander Isakov, MD, MPH, is a professor of emergency medicine at Emory University School of Medicine. He is certified by the American Board of Emergency Medicine in both emergency medicine and emergency medical services (EMS). Dr. Isakov is the director of the Section of Prehospital and Disaster Medicine whose faculty provides medical oversight for 911 communications centers, and ground and air EMS responders in metropolitan Atlanta. He is also the executive director of the Emory Office of Critical Event Preparedness and Response (CEPAR), which serves as the center for Emory enterprise-wide planning for and coordinated response to catastrophic events. Dr. Isakov has provided leadership in emergency medical services and disaster preparedness locally and nationally. He serves as the medical director for the Sandy Springs Fire Department and Air Life Georgia. He is the founding medical director for the Emory-Grady EMS Biosafety Transport Program. He is the EMS lead for the National Emerging Special Pathogens Training and Education Center (NETEC) and is a designated Subject Matter Expert for the Assistant Secretary for Preparedness and Response, Technical Resources, Assistance Center, and Information Exchange (ASPR TRACIE). Dr. Isakov is also on the American College of Emergency Physicians Epidemic Expert Panel and is a member of the EMS sub-board for the American Board of Emergency Medicine. He previously served on the National Association of EMS Physicians board of directors and the Technical Expert Panel for NHTSA's EMS Agenda 2050. Dr. Isakov has an MD from the University of Pittsburgh and an MPH from Boston University. He completed his emergency medicine residency training at the University of Massachusetts Medical Center and his EMS fellowship with Boston EMS. Dr. Isakov has lived and worked in Atlanta for 20 years. He practices clinically in the emergency department of Emory University Hospital. RATE AND REVIEW THE EMS ONE-STOP PODCAST Enjoying the show? Please take a moment to rate and review us on Apple Podcasts. Contact the EMS One-Stop team at editor@EMS1.com to share ideas, suggestions and feedback.

Leading with tenacity and purpose and demonstrating clinical excellence is the trademarked brand of my next guest Dr. Yele Aluko. He has a laser-sharp focus to withstand the daily struggles of a career cardiologist and medical consultant.  Dr. Aluko has an impeccable preparation, education, and clinical intelligence legacy.Yele Aluko MD, MBA is Chief Medical Officer in EY Americas Health Advisory practice. He advises health system C-suite and senior executives on strategy and business operations and provides insight into megatrends confronting the health industry. He is a proven physician executive and corporate leader with an astute understanding of strategy that develops competitive advantage for healthcare organizations. As Director of the EY Center for Health Equity, he leads EY teams in designing customized strategies, solutions, and competency building for health sector value chain participants seeking to achieve Health Equity.  Before joining EY in October 2016, he practiced cardiovascular medicine for 25 years at Novant Health. In this southeast regional integrated healthcare system, he led enterprise clinical integration strategy, operations management, and care delivery within the heart and vascular service line across the fifteen-hospital health system footprint.  He obtained his MBA from Wake Forest University School of Business, Interventional Cardiology Fellowship from the University of Massachusetts Medical Center, Invasive Cardiology Fellowship from Cornell University Medical Center, General Cardiology Fellowship, and an Internal Medicine Residency from the College of Physicians and Surgeons of Columbia University. He obtained his Doctor of Medicine from the College of Medicine, University of Ibadan, Nigeria.  He is certified by the American and Canadian Boards of Internal Medicine and the American Boards of Cardiovascular Medicine and Interventional Cardiology. He is a Fellow of the American College of Cardiology (FACC), and the Society for Cardiac Angiography and Interventions (FSCAI).  He is an Advisory Board member at Harvard Business Review, Honeywell Healthcare Solutions, and Children's National Hospital and is co-chair of the Health Equity Advisory Board at the International Well Building Institute.Let us Welcome Dr Yele Aluko to the Follow The Brand Podcast Where We are Building a 5 STARF Brand That You Can Follow!

The Person Who Teaches Mindfulness Download the Selfpause Affirmation App The person who teaches mindfulness can make a big difference if they are an expert in the subject. However, it is important that the messenger of mindfulness has a unique voice. A dopey yoga instructor could do more harm than good. Even a self-guided meditation app can be ruined by a dummy teacher. Jon Kabat-Zinn, a physician and meditation teacher trained at MIT, has been putting mindfulness in a scientific context since 1979. He also founded the Mindfulness-Based Stress Reduction course at the University of Massachusetts Medical Center and has conducted dozens of studies to support the effectiveness of mindfulness.

Cliff A. Megerian, MD, is Chief Executive Officer of University Hospitals (UH), a comprehensive health system with annual revenues of $5.3 billion, 21 hospitals (including 5 joint ventures), more than 50 health centers and outpatient facilities, and over 200 physician offices located throughout 16 counties. He assumed this position in February 2021 and joined UH in 2002. He is also the Jane and Henry Meyer Chief Executive Officer Distinguished Chair.In December 2019, Dr. Megerian was appointed the system's President, where he led the organization through an unprecedented pandemic. Prior to that, he served as President, University Hospitals Physician Network, Physician Services and System Institutes. In these positions, he was charged with managing the clinical integration strategies, policies and practice guidelines for more than 2,500 UH employed physicians as well as the operations and infrastructure for UH system institutes. These clinical care institutes bring highly trained subspecialists together from multiple disciplines to collaborate on the best treatment for patients – promoting uniform, standard care protocols and the sharing of best practices.Additionally, he raised physician productivity to its highest level and significantly increased physician engagement and research funding. UH's physician network includes the full-time academic medical practice at UH Cleveland Medical Center and UH's community-based, multi-specialty physician network throughout Northeast Ohio.Dr. Megerian is also a Professor in the Department of Otolaryngology, Head and Neck Surgery at Case Western Reserve University (CWRU) School of Medicine, where he was Chair from 2012 – 2018 and held the Julius McCall Professorship at CWRU, as well as the Richard and Patricia Pogue endowed Chair in Auditory Surgery and Hearing Sciences at UH. He also serves as an Adjunct Professor of Surgery at Northeast Ohio Medical University.Prior to UH, he served on the physician staffs of the Louis Stokes Cleveland Veteran Affairs Medical Center and MetroHealth System Medical Center. At the University of Massachusetts Medical Center, Dr. Megerian was the Director of Otology and Neurotology, as well as the Director of Residency Training, the Medical Director, Cochlear Implantation Program, and the Co-Director, Center for Skull Base Diseases. He also served on the medical staff of Massachusetts Eye and Ear Infirmary and Boston Medical Center.Dr. Megerian's clinical career has been devoted to the management of hearing loss, chronic ear disease, cholesteatoma, otosclerosis, vertigo, and other otology and neurotology issues. As a surgeon, Dr. Megerian co-founded UH's Cochlear implant program and he and his team have performed over 1,500 cochlear implant surgeries, making it one of the largest programs in the country.He is also an expert in the diagnosis and treatment of acoustic neuroma. He has published over 130 peer-reviewed manuscripts and abstracts and has served as visiting professor at numerous medical schools and institutions throughout the world.His research interests in the pathogenesis of Meniere's disease have been funded by a number of agencies including the NIH and DRF. He previously served as a consultant to the FDA in the regulation of Ear, Nose and Throat Devices. He is co-author of a textbook in its second publishing, “Surgery of the Cerebellopontine Angle.”Dr. Megerian is a graduate of the University of Michigan Medical School and completed a residency in otolaryngology-head and neck surgery at University Hospitals of Cleveland and CWRU. He completed a research and clinical fellowship in otology and neurotology at Harvard Medical School, Massachusetts Eye and Ear Infirmary. He also completed a certificate program in healthcare management at Weatherhead School of Business at CWRU.Dr. Megerian serves on the American Hospital Association's Health Systems Committee. In addition, he serves on the boards of the Ohio Hospital Association, the Ohio Business Roundtable and the Greater Cleveland Partnership. He is also Chair of the Cleveland Innovation District/Jobs Ohio Consortium.In 2022, Becker's Healthcare named Dr. Megerian one of 113 Great Leaders in U.S. Healthcare and one of 7 Highly Successful Health System CEO-CFO Duos. Ohio Business Magazine appointed him to the Ohio 500, recognizing the most powerful and influential leaders who are working to make Ohio great. Crain's Cleveland Business named Dr. Megerian to the Power 150 – a list of executives leading some of Northeast Ohio's most influential organizations who are in a position to move the region forward.As CEO of University Hospitals, Dr. Megerian also led the system to attain the 2022 AHA Quest for Quality Prize – the industry's most prestigious honor recognizing its member organizations for their commitment to quality. Dr. Megerian and his wife Lynne Sheffler Megerian, MD, reside in Shaker Heights. They have three adult children.Visit University Hospitals: https://www.uhhospitals.org/

Dr. Abadi received his Doctor of Medicine from the University Of Vermont College of Medicine in Burlington, Vt., where he was elected to the Alpha Omega Alpha Medical Honor Society. He completed his Internal Medicine residency and Cardiology fellowship at the University of Massachusetts Medical Center in Worcester, Mass. He completed a clinical research fellowship in Echocardiography at Tufts-New England Medical Center in Boston. Dr. Abadi is board certified in cardiovascular disease and all disciplines of Echocardiography. He is a member of the American College of Cardiology and the American Society of Echocardiography. His areas of special interest are valvular heart disease, aortic disease, and atrial fibrillation. He also has a strong interest in trans-esophageal echocardiography and 3-dimensional echo, providing support for many advanced catheter-based and cardiac surgical procedures. He will discuss his role at Southcoast Health, how to prevent heart disease, the importance of not delaying care when experiencing symptoms, services provided by Southcoast Heath, and much more.

Dr. Abadi received his Doctor of Medicine from the University Of Vermont College of Medicine in Burlington, Vt., where he was elected to the Alpha Omega Alpha Medical Honor Society. He completed his Internal Medicine residency and Cardiology fellowship at the University of Massachusetts Medical Center in Worcester, Mass. He completed a clinical research fellowship in Echocardiography at Tufts-New England Medical Center in Boston. Dr. Abadi is board certified in cardiovascular disease and all disciplines of Echocardiography. He is a member of the American College of Cardiology and the American Society of Echocardiography. His areas of special interest are valvular heart disease, aortic disease, and atrial fibrillation. He also has a strong interest in trans-esophageal echocardiography and 3-dimensional echo, providing support for many advanced catheter-based and cardiac surgical procedures. He will discuss his role at Southcoast Health, how to prevent heart disease, the importance of not delaying care when experiencing symptoms, services provided by Southcoast Heath, and much more.

Anna Humphreys, the co-director of Calm Birth, shares why this project of healing meditations for abortion is essential.  Restore, the second meditation in the series is based on the practice of opening, a healing progressive relaxation meditation. The method is based on Progressive Relaxation techniques developed by Edmund Jacobson, M.D., at the Harvard Medical School and the University of Chicago Medical School in the 1920s and 1930s. A wide range of medical problems were successfully treated by healing corresponding problems in the nervous system. The method was then further developed in the University of Massachusetts Medical Center's medicine/meditation program beginning in 1979. The body responds to stress with muscle tension, which can cause pain or discomfort. In turn, tense muscles relay to the body that it's stressed. That keeps the cycle of stress and muscle tension going. Progressive muscle relaxation helps break this cycle by reducing muscle tension and general mental anxiety.  This practice is useful for sleep and rest."I've seen abortions be incredibly difficult decisions for people whether it's something they know they want or their life circumstances didn't allow for a child at the time. Either way, it is a challenging physical experience to release a pregnancy and the healing is rarely honored. That's why I am so glad that we had this practice of progressive relaxation to draw from that I'm intimately familiar with from the Calm Birth program but that applies so well to recovering from an abortion, especially at a time when the female body is being increasingly commodified and criminalized. ...Abortion meditations won't fix the systemic problems that allow these laws to pass, but I think it's an important drop in the bucket. I also love that they're gender-inclusive, because we know abortion is non-binary. These meditations are for everyone, and I hope they reach anyone who could use some extra support."—Anna Humphreys For those of us at Calm Birth meditation that have been working on this Calm Abortion project, it is our hope that these meditations help to invite healing for whoever chooses to listen, no matter how long ago they experienced an abortion for any reason or circumstance.Learn more about the Calm Abortion meditations at Instagram @calmabortion   and  Facebook @calmabortionResources:ACOG (The American College of Obstetricians and Gynecologists) Statement on Abortion BansWorld Health Organization's statement on abortionEvidence Based Birth: Abortion Research Resource GuideGrief After Abortion: healing from unspoken loss 

While none of us wants to ever need to call 911, the truth is, many of us will. It is good to know that emergency medical professionals are required to follow infection prevention and control best practices but that is not always so easy. This episode sheds light on the unique needs of the EMS professional setting. Hosted by: Silvia Quevedo, CAE About our Guests: Alexander Isakov, MD, MPH Dr. Isakov is a Professor of Emergency Medicine at Emory University School of Medicine and the director of Emory's Section of Prehospital and Disaster Medicine. He is also the Executive Director for Emory's Office of Critical Event Preparedness and Response. Dr. Isakov is on the American College of Emergency Physicians Epidemic Expert Panel. He is the EMS lead for the National Emerging Special Pathogens Training and Education Center (NETEC) and is a designated Subject Matter Expert for ASPR TRACIE, with whom he led the development of the EMS Infectious Disease Playbook. He is the medical director for the Emory-Grady EMS Biosafety Transport Program. Dr. Isakov has an MD from the University of Pittsburgh and an MPH from Boston University. He completed his residency training at the University of Massachusetts Medical Center and his EMS fellowship with Boston EMS. Dr. Isakov practices clinically in the emergency department of Emory University Hospital in Atlanta, GA. Jill Holdsworth, MS, CIC, FAPIC, NREMT, CRCST Jill obtained a Bachelor of Science from West Virginia Wesleyan College in Biology and a Master of Science from Marshall University in Exercise Science. She began her career as a cardiac rehab therapist in Huntington, WV. Jill began working as an IP in 2009, obtained her CIC after 1 year in the field, and became a Fellow of APIC in 2016. Jill became involved in APIC in 2009 with the DC Chapter, becoming the secretary in 2012, President-Elect in 2013 and the President in 2014. Jill was the 2015-2016 APIC Emergency Management Committee Chairman and is currently the AAMI Protective Barriers Committee co-chair. Jill is a certified EMT and is certified in sterile processing through IAHCSMM. She is currently working in Atlanta, GA as the Manager of Infection Prevention at Emory University Hospital Midtown.  

Do you have ADHD or does your child? Ever wonder why it happens—and what to do? Having trouble finding help? What's coming out of ADHD research these days? From why ADHD presents in a person to medication to the frontier of research on ADHD treatment and emerging neuroimaging methods, Dr. Russell Barkley joins The Most Days Show to pull back the curtain on this genetic disorder.   Dr. Barkley is a prominent voice in the field. Now retired from the Virginia Commonwealth University Medical Center as Clinical Professor of Psychiatry, he was also previously a Professor of Psychiatry and Neurology from the University of Massachusetts Medical Center and a Professor of Psychiatry and Health Sciences at the Medical University of South Carolina.    Give it a listen here.

In this episode, I am delighted to be reviewing the book, "Taking Charge of Adult ADHD", - 2nd edition with author Russell Barkley, PhD.    This is a must-have book for all adults with ADHD! and a must-listen conversation  We talked about: - Latest research in ADHD - Medication and ADHD - what's on the horizon - Emotional dysregulation  - How to move past the diagnosis and take charge of your ADHD and sooo much more.  Be sure to order the 2nd edition of Taking Charge of Adult of ADHD    Additional resources - http://www.russellbarkley.org/factsheets.html The ADHD Report - http://www.russellbarkley.org/newsletter.html   About Dr. Barkley  Russell A. Barkley, Ph.D., is a Clinical Professor of Psychiatry at Virginia Commonwealth University School of Medicine (2016-present).  He is also a retired Professor of Psychiatry and Neurology from the University of Massachusetts Medical Center (1985-2002) and subsequently worked as a Professor of Psychiatry and Health Sciences at the Medical University of South Carolina (2003-2016).  In semi-retirement, he continues to lecture widely and develop continuing education courses for professionals on ADHD and related disorders, as well as consult on research projects, edit The ADHD Report, and write books, reviews, and research articles. He is board-certified in Clinical Psychology (ABPP), Clinical Child and Adolescent Psychology, and Clinical Neuropsychology (ABCN, ABPP).  Dr. Barkley is a clinical scientist, educator, and practitioner who has published 27 books, rating scales, and clinical manuals numbering more than 43 editions, and creator of 7 award-winning professional videos.  He has also published more than 300 scientific articles and book chapters related to the nature, assessment, and treatment of ADHD and related disorders.  He is the founder and Editor of the clinical newsletter, The ADHD Report, now in its 29th year of publication.  Dr. Barkley has presented more than 800 invited lectures in more than 30 countries and appeared on nationally televised shows such as 60 Minutes, the Today Show, Good Morning America, CBS Sunday Morning, CNN, and many others.  He has received numerous awards from professional societies and ADHD organizations for his lifetime achievements, contributions to research and clinical practice, and the dissemination of science.  His website is www.russellbarkley.org.

This month on Episode 28 of Discover CircRes, host Cynthia St. Hilaire highlights four original research articles featured in the August 20th and September 3rd issues of Circulation Research. This episode also features an in-depth conversation with Dr Scott Cameron from the Cleveland Clinic and Dr Milka Koupenova from the University of Massachusetts Medical Center about their study, SARS-CoV-2 Initiates Programmed Cell Death in Platelets.   Article highlights:   Gupta, et al. Electronic Cigarettes and Oxidized Lipids   Bartosova, et al. Glucose Derivative Induced Vasculopathy in CKD   Atmanli, et al. DMD Correction Attenuates Cardiac Abnormalities   Ma, et al. Length Dependent Activation in Porcine Myocardium   Cindy St. Hilaire:        Hi, and welcome to Discover CircRes, the podcast for the American Heart Association's journal, Circulation Research. I'm your host, Dr Cindy St. Hilaire from the Vascular Medicine Institute at the University of Pittsburgh, and today I will be highlighting articles presented in our August 20th and September 3rd issues of Circulation Research. I also will speak with Dr Scott Cameron from the Cleveland Clinic and Dr Milka Koupenova from the University of Massachusetts Medical Center about their study, SARS-CoV-2 Initiates Programmed Cell Death in Platelets. Cindy St. Hilaire:        The first article I want to share is titled Electronic and Tobacco Cigarettes Alter Polyunsaturated Fatty Acids and Oxidative Biomarkers. The first author is Rajat Gupta and the corresponding author is Jesus Araujo from UCLA. E-cigarettes have surged in popularity in the last decade and while many people switching from traditional cigarettes to smokeless ones view the latter as a safe alternative to smoking tobacco, emerging data shows that E-cigarettes cause adverse effects such as oxidative stress, inflammation and endothelial dysfunction in users. The aerosols produced during vaping contain similar levels of reactive oxygen species, also called ROS, as the vapors of tobacco smoke. However, data on the extent to which E-cigarettes, E-cigarette ROS, influences cardiovascular health is lacking. Cindy St. Hilaire:        To address this, this group recruited 32 chronic users of E-cigarettes, 29 chronic tobacco smokers, and 45 individuals that used neither and they measured their plasma levels of oxidative biomarkers. The team found both similarities and differences between the E-cigarettes and the tobacco users. For example, both smoking groups had increased plasma antioxidant capacity and decreased levels of oxidized linoleic acid compared with the levels seen in non-users, while arachidonic acid levels were raised in tobacco smokers and reduced in E-cigarette users. Overall, however, the biomarker levels were deemed to be intermediate for E-cigarette users between the non-users and the tobacco users. This study suggests that while E-cigarettes carry a lower health risk than tobacco, they are by no means safe.     Cindy St. Hilaire:        The second article I want to share is titled Glucose Derivative Induced Vasculopathy in Children on Chronic Peritoneal Dialysis. The first author is Maria Bartosova and the corresponding author is Claus Schmitt and they're from the University of Heidelberg. Diabetes, high blood pressure and obesity are risk factors for both cardiovascular disease and chronic kidney disease. Worse still, loss of kidney function and even dialysis itself are thought to exacerbate cardiovascular issues. In the case of dialysis, it's thought that high levels of glucose degradation products, or GDPs, in the dialysis fluids can promote the addition of sugar moieties to vascular proteins and lipids causing vascular damage. To investigate this theory, Bartosova and colleagues studied vascular tissue from children with chronic kidney disease receiving dialysis fluids with either high levels or low levels of glucose degradation products and compared these to tissues from children not on dialysis at all. Cindy St. Hilaire:        Proteome and transcriptome analysis of the vessel tissues revealed that compared with patients or no to low GDP fluids, patients receiving high GDP fluids had higher levels of damaging glycation, increased transcription of genes involved in cell death, and decreased transcription of genes involved in cell survival and cytoskeletal reorganization. In line with these findings, vessels from high GDP patients displayed considerable evidence of damage, such as markers of apoptosis, skeletal disintegration and thickened intimas. The results confirmed GDPs can cause vasculopathy and suggest low GDP fluids should be used for dialysis patients. Cindy St. Hilaire:        The next article I want to share is titled Cardiac Myoediting Attenuates Cardiac Abnormalities in Human and Mouse Models of Duchenne Muscular Dystrophy. The first author is Ayhan Atmanli and the corresponding author is Eric Olson from UT Southwestern. Duchenne Muscular Dystrophy, or DMD, affects one in 5,000 baby boys and is caused by mutations in gene for dystrophin, an architectural protein essential for muscle cell integrity. Patients display profound muscle degeneration and weakness, with respiratory and heart muscle dysfunction being a major cause for death. With the recent improvements in respiratory medicine that extend the lives of patients, this group now focused on heart dysfunction and specifically, whether gene editing could mitigate it. The team created induced pluripotent stem cells, or iPSCs, from Duchenne Muscular Dystrophy patient and his healthy brother and showed that gene editing from the DMD cells enabled their development into normal-looking cardiomyocytes with normal contractile function and calcium handling, equivalent to that seen in healthy control cells. The unedited DMD cells, by contrast, did not develop normally. For great clinical relevance, the team edited DMD cells after cardiomyocyte differentiation showing that this reduced their propensity for arrhythmia, compared with that of unedited cells. Cindy St. Hilaire:        Lastly, the team provided evidence to suggest gene editing may improve heart abnormalities in mice with the same mutation. All together the results are proof of principle and support of the development of gene editing therapy as treatment for DMD. Cindy St. Hilaire:        The last article I want to share is titled The Super-Relaxed State and Length Dependent Activation in Porcine Myocardium. The first authors are Weikang Ma and Marcus Henze and the corresponding author is Thomas Irving and they're from the Illinois Institute of Technology. Myofilament length-dependent activation or LDA is the fundamental mechanism coupling the force of the heart's contraction to it's proceeding diastolic volume. In other words, LDA ensures that the more the heart fills, the stronger it contracts. Studies of rodent hearts have given insights into LDA mechanics. However, how it operates in large mammalian hearts is unknown. Using structural and biochemical analysis of pig myocardial fibers, this group found that compared with small stretches of the fibers which were equivalent to small diastolic volumes, long stretches induced greater ATP turnover and greater numbers of cross bridges between myosin and actin filaments which are critical contractile machinery proteins. Cindy St. Hilaire:        Myosin motors can be found in three stages, engaged with actin, unengaged in a disordered, relaxed state but ready to engage, or super-relaxed state where they are essentially switched off. The team showed that as muscle stretch increased, the amount of super-relaxed myosin motors diminished with more myosin motors becoming engaged to enable a stronger contraction. When the fibers were treated with a myosin motor inhibitor, these stretch effects were impaired. In revealing the mechanisms of myofilament length-dependent activation, this study provides a platform for studying cardiomyopathies in which this system goes awry. Cindy St. Hilaire:        So today, Dr Scott Cameron from the Cleveland Clinic and corresponding author of the paper, Dr Milka Koupenova from the University of Massachusetts Medical Center, are both with me to discuss their study, SARS-CoV-2 Initiates Programmed Cell Death in Platelets. And this article is in our September 3rd issue of Circ Research and for full disclosure, the editor of Circ Res, Dr Jane Freedman is also an author on this manuscript. And for full double disclosure, I know Dr Koupenova quite well as we were both graduate students together back in the Ravid Lab at Boston University. However, the full Editorial Board selects these articles, not just me alone and this one is timely, novel, and an amazing story. So thank you both for joining me today. Milka Koupenova:       Thank you for having us. Scott Cameron:           Privileged to be here. Cindy St. Hilaire:        So before we jump into the story that is your paper, can you give us a little bit of background about platelets? I know for years, I guess certainly before Katya's lab, I just thought of platelets as little nucleus-free particles that clot. But we know they are so much more than that. So why are they so important? And how do they function to do more than just stop a bleed? Milka Koupenova:       So this is a great question, Cindy, and I am happy that you alluded exactly to the anucleated nature of platelets. So platelets are cell fragments. They're precursors in the bone marrow, the megakaryocyte. They are the second most abundant blood component after the red blood cells. And traditionally, platelets have been known, as what you pointed out, as these little units that change their conformation once there is some form of a problem with either the vascular, which we have a cut, they come together, they form this clot, and bleeding is prevented. But as we have learned perhaps in the past 20 years that platelets have a profound immune role during various immune processes and infections for different kind of microbes. And particularly relevant to this paper is that we understand that platelets have clearly a role responding to the viruses and activating the immune system. Cindy St. Hilaire:        Yeah, and that was actually my next question. You and Jane are the world-leading experts on platelets and viral responses. So what was known about that interaction, I guess before we started looking at SARS-CoV-2, what was known about that platelet virus or even type of virus interaction? Milka Koupenova:       So SARS-CoV-2 is a RNA virus--respiratory virus that we actually thought similarly to influenza that it mostly stays in the lower respiratory tract where it becomes problematic. However, from our work with influenza, when we saw that in certain patients you actually can detect the virus in platelet. In the beginning of the pandemic, we hypothesized that perhaps, in some people, the virus crosses over into the circulation. And based on our previous studies with influenza, we wanted to see if that indeed is the case. Hence we initiated a study here at UMass with the department head who is also on the paper, Dr Finberg, who is a leading expert in influenza and novel virus and we collected platelets from people to see if we can detect it. And so in the beginning, we were not able to detect SARS-CoV-2 in platelets. So we collected platelets from 17 patients and by qPCR with the primers that the CDC has, for whatever reason I couldn't detect anything. And I was really frustrated because previous reports have shown that about 25%, in some people even 35% of the study population, SARS can be detected. So very interesting observations. Milka Koupenova:       I could see it by immunofluorescence but I couldn't detect the RNA. And the story goes, that I attended a seminar on SARS-CoV-2 and the person was actually referencing a company that started from University of Pitt where you are. Cindy St. Hilaire:        Oh, very nice. Milka Koupenova:       And they do specific, it's called amplicon ARTIC v3 sequencing so they enrich for the SARS-CoV-2 RNA and screen by sequencing. And when we did that, we were able to detect it in all patients. So I freaked out and I said, "Oh my gosh, something is wrong." Milka Koupenova:       And so I sent plasma, and I sent controls, and actually RNA from the virus and you can see beautifully that it's only in platelets. Four of the 17 people actually had RNA in the plasma, but what you can observe in all these people is that the virus is fragmented, meaning it's not infectious. And in a way what this tells us, it suggests that platelets are super important in the removing it from the circulation and they probably serve as a dead-end for the virus because you cannot find virus coming out of platelets and the RNA is chopped off. So what I would say, is that platelets are these amazing little units that serve as removal of the viral RNA for these particular viruses, respiratory viruses that are RNA viruses. Cindy St. Hilaire:        I think that is so interesting. So essentially, they're almost like little composters that are chewing it up and preventing it from spreading in the organism. Milka Koupenova:       Yes, and as a result there is a response. Cindy St. Hilaire:        Scott, probably the most common thing that people know with SARS is that loss of smell, or taste, and things like that, but really that doesn't send anybody to the hospital. So really what are the symptoms of COVID-19 patients that tie in with platelets specifically? I feel like that's a lot of things that we maybe in the public, or on Twitter, and things didn't hear as much about. So really what are those big symptoms linking COVID and platelets and what are the implications of platelet death in the pathogenesis of COVID? Scott Cameron:           So certainly I think several investigators are in the world of now showing that platelets are hyperactivated, Robbie Campbell and Matt Rondina put a really nice paper in Blood last year showing that platelets are hyperactive and there are other investigators who found something similar. And so the question is, what are the symptoms of hyperactive platelets in the SARS-CoV-2 patient? So what most of them would find is shortness of breath or dyspnea, and when they present to the emergency department, and certainly we saw this, the oxygen saturation which should be in the mid to high 90s on room air on an average person, was quite often low. It was in the 80s or 70s, sometimes even the 60s. Scott Cameron:           And the real surprising thing was those are patients that would normally immediately be on a ventilator, but yet they could still be talking to you. And so if you have a platelet that's activated in a hyperthrombotic condition, like SARS-CoV-2, COVID-19, and then that forms a blood clot, you have a situation where the amount of oxygen the patients taking in and the amount of oxygen you're measuring in the artery is quite discrepant and we call that the alveolar arterial or oxygen gradient. So if you've got lots of platelet plugs through the microvasculature, it's going to take up some space the oxygen should be using for diffusing in. And so that would be manifested as shortness of breath and that's certainly one of the biggest tip-offs that a patient might have a blood clot, particularly in the lung. Cindy St. Hilaire:        Some of these symptoms of COVID-19 are really worse in patients with comorbidities, diabetes, obesity and heart failure. Are platelets central to kind of the pathogenesis of those disease or the symptoms of those diseases? I guess the root of my question is, why do the comorbidities of diabetes, obesity, and heart failure make COVID worse? Is it something about those disease states themselves or is there a role for platelet? Scott Cameron:           That's a brilliant question, no one's ever asked that before. And as Dr Koupenova said, I'm a little bit biased too because I firmly believe that in different disease states, the disease educates the platelets so you've got a different platelets phenotype. So focusing on diabetes, we know the platelet phenotype is different in diabetic patients. We know that platelet reactivity seems to be higher through the P2Y12 receptor.  In terms of obesity, it is true, we know that, and this has been published also, and we know that the platelet phenotype is hyperactive in a patient with obesity and so that tells me that, that's a comorbidity that might affect platelet function and also vice versa for that case. And then in terms of why is it affecting males more prominently and more severely than females, well one of the beefs, I guess, that I had is that we treat diseases in women the same as we do in men assuming that the platelet phenotype in disease must be the same, but that's absolutely not true. And that's actually a theme that we have in our lab right now, we know that the behavior of platelets, and how platelets are educated in diseases is not all the same in women as in men and I think it's a huge disservice that we really had to have a pandemic that would make that quite clear to us. Cindy St. Hilaire:        You kind of hit onto something that's really, I think it's now becoming more recognized certainly in the cardiovascular field and that is so many studies are really only on male mice, or only younger or older men, and we are missing not only a huge patient population, but probably some really interesting biology that is distinct. Milka Koupenova:       So expanding on that, we know that in platelets, the toll-like receptors, and we've looked at the expression of all 10 in a study that we published in ATVB in 2015, actually, significantly if you look at Farmingham Heart Study data and the expression of these toll-like receptors they are increased in women versus men. And also, an interesting observation that never got published, once upon a time when I was doing studies with TLR7 mice is that if you inject TLR7 agonists, male mice would have a higher level of reduced platelet count than female mice at the same time points, right? And at that time it wasn't published. Definitely there are differences, but I also want to extrapolate a little bit on what was said at the beginning. We have to understand that when it comes to these comorbidities, everything affects a unit that doesn't have a nucleus, right? And diabetes and obesity have the so called profound, chronic inflammation of cytokines, such as IL6, that keep circulating. These things have effect on platelets. So we have two responses, we have the environment that affects platelets and we have the direct response of the virus that affects platelets. And that cumulative response truly can exhaust them and once they become exhausted, once they release their contents, as we show in this paper, then you're compromising their function and you will be compromising taking out the virus from one side and from the other side you're going to be compromising the environment because all of the content that comes out from a unit that already has free form proteins, it exhibits a true insult on what's being surrounded. So these clots that form in the lung or the platelets that circulate they no longer can be resolved properly. Cindy St. Hilaire:        Yeah. Milka Koupenova:       It's a balance. Cindy St. Hilaire:        Yeah, so really it's like destroying the platelet not only are you destroying the vacuum that has to suck up those particles, you're then just dumping a whole bunch of pro-inflammatory things on all of the endothelial cell vasculature that those platelets are nearby. Cindy St. Hilaire:         Actually that was one thing that I thought you spent a decent portion of the discussion on, and that is the method by which the blood is collected really impacts the outputs you observe in quote unquote platelets. Can you talk about the importance of that because I think that's one thing, certainly as a PhD who's just like, "Oh, yeah. I'm just going to collect blood from my mice and do this thing," how critical is that point in the experiment, in the blood collection? Milka Koupenova:       So I am very adamant when it comes to platelets for the blood to be drawn in citrate. And I have to say that a lot of the studies that you would see in the literature are done using EDTA blood or serum. They all have their importance. I'm not going to dismiss it, but if you want to truly measure what's inside in plasma, versus what's inside in platelets, or what's inside in any cell for that matter, you got to go for citrate. You have to be very careful not to shake the blood. You have to be very careful not to cool down the blood. So the nurses probably hated me because often I would be like, "You can't do this. You can't put it on ice. You can't warm it up to above certain degrees. Everything has to be controlled and done correctly." Milka Koupenova:       And so I had done in the past studies in which I would take plasma from the same patient in EDTA, in citrate and then isolate the RNA, have my tech isolate the RNA, and we send it to a fragment analyzer, and you can see how much more RNA you will get in the EDTA plasma. I'm not even talking about serum. Milka Koupenova:       Serum is a very different thing, then you're definitely going to get platelet content in it, in the serum, right? So it's important to distinguish that perhaps when you're getting EDTA plasma you are looking at a content that could have been inside in platelet and I can't stress enough that when it comes to these particular studies, citrate, dextrose, phosphate is your place to go and be. Cindy St. Hilaire:        So in terms of translational potential, what do your findings suggest about future therapies or targets to investigate as therapy? And is modulating platelets a potential for combating viral infections or mitigating their severity? Milka Koupenova:       Well, Scott and I actually talk a lot about that. Scott Cameron:           That's right. Milka Koupenova:       I personally would say, control the inflammation, never let it go to platelet. Let me back up a little bit, if you have to, you have to, right? But your go to method should be inflammation, if you don't get to the point that you need to control platelets then you're in a better place because it becomes very fickle. From everything that you hear me say, you push it to one side and the balance is destroyed. You deactivate platelets or inhibit platelets well, are they now not able to pick up the virus and then you're now having the virus circulating somewhere. Now, if you don't treat platelets that's also not good. So you're in the very fickle situation if you get to the point that you need to control the activation of platelets and there are trials currently that are trying to look at those things. Scott, I'm going to refer this a little bit more to you because you have done some interesting things with that particular point. Scott Cameron:           No, it's a great question, Milka, and I think that as platelet biologists, nobody more than I wanted it to be true that platelets would be the ultimate target. I mean, clearly patients with SARS-CoV-2 have thrombosis, clearly platelets are activated, so should we inactivate them? That was the whole point of the RECOVERY trial and one of the benefits I'll tell you before I sort of go into that is, working in a large organization like the Cleveland Clinic and we have access to data and lots of it extremely quickly, and so because of that I of course could see how many patients were coming into our hospital with thrombotic events. And I could see what the independent predictors of thrombotic events was and it wasn't the platelet count, sometimes platelet count was low, sometimes it's high in the SARS-CoV-2 patient. And if you took those individuals that were on aspirin, comparing them to those that are not in a propensity match study,  one of the things that we find is that aspirin doesn't seem to affect or improve mortality or the number of blood clots in the patient with SARS-CoV-2. Scott Cameron:           We compared that to all non-steroidal anti-inflammatory medications that patients may have been taking also in a propensity match study just in case it was the mechanism action of the drug, rather than the drug itself, and we found that NSAIDs not only did not protect patients, but they were not necessarily harmful either, which was one of the things that came out at the start of the pandemic. Among, I'll add, the absence of evidence based medicine and a lot of cases where naturally people, including clinicians, were scared and so they were going off label and they were trying a lot of different medications with really not a shred of randomized controlled data. Scott Cameron:           But now that we're 18 months into it, the first and biggest study that came back was the RECOVERY trial, which we were all waiting on, where patients were given aspirin and short term mortality was examined over an observational period of one month. And just like we found in a propensity match study, which is as close as you'll get to a clinical trial in a retrospective manner, the prospect of RECOVERY trial actually showed the curves were almost super imposeable, those that got aspirin versus those that didn't. So I think low dose aspirin clearly is not going to be enough for those patients, but I'll also add that over the observational period of one month they also didn't see a higher incidence of death in those patients. And I think Milka's point is really well taken that you have to remember that as well being an entity of thrombosis, platelets are immunological entities and so you've got to really consider should we be inhibiting them and if you are inhibiting them, I think the time point at which you should inhibit them is what we should examine, not just an all or nothing, inhibited or not. Milka Koupenova:       It's just in our linear brains we prefer to think of it as one straight, linear pathway, but it isn't, and I think platelets are actually a great example of how many pathways are feeding into one tiny fragment and that particular blood cell is inducing this profound response during these infections. Cindy St. Hilaire:        I think most people have heard that angiotensin-converting enzyme 2, also called ACE2 is the receptor of SARS-CoV-2. The virus itself uses it to bind and become internalized into the cell, but there's been some discussion or even some discrepancy of data as to whether platelets truly express ACE2 and if that is the means for the virus to enter the platelets. So can you share with us what is the current state of knowledge about that? Scott Cameron:           Yeah, just as a segue of some of the things that Milka said, I think the preparation of your sample is part of the answer. If you draw in the incorrect tube, if you the tube is not completely filled, and the ratio of citrates to whole blood isn't correct you're going to have discrepant results. If you biomechanically activate the platelets by drawing through a short needle, in a small-bore needle for example, that's going to activate the platelets. If you cool them, it's going to activate them. But then also, depending on how you decide to separate them, we always washed platelets in my lab, we wash them two or sometimes three times, and I can tell you if you use flow cytometer we get one white blood cell for every 12,000 platelets. Scott Cameron:           And some investigators might go one step further and they'll a CD45 depletion set, which is certainly important if you're studying RNA. But one of the issues, as you well know, a CD45 is also on the surface of platelets, so if you start with a low expressing protein and you CD45 deplete them, you are actually going to get a decrease in your platelet yields. I've seen it, I think Milka's seen it, various other investigators have, and you might find yourself at the threshold of what your antibody can detect. It's also variably expressed. If you look at even healthy individuals, some of them have almost none. So if you look at 10 individuals, you might actually find none, but then if you look at another 10, the amount of expression that we see is kind of all over the place. It's not like other receptors where one tends to express a certain amount and that's the way it is in health. ACE2 doesn't seem to be that way for whatever reason. Milka Koupenova:       We were able to detect in some of the people by qPCR, but what was interesting is that from the three primers that I used there was never the same person who we were able to detect all three primers with for that receptor. That tells you that maybe they are changes of one base that is not enough for the primer to detect it, right? That becomes another possibility of not being able to detect. Milka Koupenova:       And so I go to confocal microscopy where I use 100 lens and tons of hours in the microscope room, and Scott is completely right, it's really hard to see it particularly in healthy people. And it starts to pick a little bit more in people with cardiovascular disease or people with COVID that are old. So it's a bit complicated, but the important thing here is, besides the fact that we are detecting ACE2 and we're detecting proteins and I use controls, biological controls to prove that this is the case and it's not just an antibody problem, is that the virus will get picked up by platelets even if you don't have ACE2. That is the take home message from this paper is that the platelet has evolved various mechanisms by which is utilizes getting it inside. It is that important for this virus. This type of virus is not recirculating. In this case, what we observed is that the virus is attached to microparticles that are of platelet origin for that matter. Cindy St. Hilaire:        So really what you're saying, what I'm hearing is the platelet is the superhero of the body. Milka Koupenova:       Definitely. Absolutely. No bias, absolutely. Cindy St. Hilaire:        Unbiasedly, it is a superhero. Well, Dr Cameron and Dr Koupenova, thank you so much not only for this amazing discussion, but for really an elegant, elegant paper that is really bringing to light the complex interaction between SARS-CoV-2 and platelets. So thank you so much for joining me and keep publishing amazing stories like this. Milka Koupenova:       Thank you for having us. Scott Cameron:           Thank you, an honor to be here. Thanks again. Cindy St. Hilaire:        That's it for the highlights from August 20th and September 3rd issues of Circulation Research. Thank you for listening. Please check out the CircRes Facebook page and follow us on Twitter and Instagram with the handle @CircRes and #DiscoverCircRes. Thank you to our guests, Dr Scott Cameron and Dr Milka Koupenova. This podcast is produced by Ashara Ratnayaka, edited by Melissa Stoner, and supported by the editorial team of Circulation Research. Some of the copy text for the highlighted articles is provided by Ruth Williams. I'm your host, Dr Cynthia St. Hilaire, and this is Discover CircRes, your on-the-go source for the most exciting discoveries in basic cardiovascular research. This program is copyright of the American Heart Association, 2021. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors or of the American Heart Association. For more information, please visit ahajournals.org.  

Many drugs are currently being investigated in attacking or supplementing the complement cascade for the treatment of geographic atrophy. We review, with the help of Dr. Johanna Seddon, Professor of Ophthalmology, University of Massachusetts Medical Center the basic biology that underlies these treatments, and assess their clinical potential.

In this episode of The Healers Café, Dr. Manon Bolliger ND, talks to Hilary Crowley who discovered her interest in the healing arts as the grandchild of three doctors & has studied with leaders in energy medicine and medical intuition.  She is the author of The Power of Energy Medicine: Your Natural Prescription for Resilient Health; Skyhorse/Simon & Schuster 2021. For the transcript and full story go to: https://www.drmanonbolliger.com/hilary-crowley   Highlights from today's episode include: Hilary Crowley 10:56 To be honest, and to show honesty, and honesty beyond the point where you're trying to make yourself sound smarter than you are or more knowledgeable or you want to hold the authority in the room. Well, when you're on is sometimes you have to say beautiful things like "I don't know". Groundbreaking words, like" let's look into it."  Hilary Crowley 15:29 As I'm listening to clarity, boundaries, balance, it certainly keeps all of the noise of what is my relationship to you. Are you approving of me? Are you all the ego stuff? It's like, well, it doesn't really matter, if you approve of me, or I know where I stand with you unconditionally. It also carries forth with integrity. Afterwards, that integrity would be another word because I'm an energy worker. Hilary Crowley But intuition for me is the body is always healing itself. And sometimes it needs help because sometimes we don't have to do it alone. So, intuition is in me listening inward to the inner intelligence of the person who's decided to share this in the room with me   About Hilary Crowley Hilary Crowley is the author of The Power of Energy Medicine: Your Natural Prescription for Resilient Health; Skyhorse/Simon & Schuster 2021. She discovered her interest in the healing arts as the grandchild of three doctors. In her early career, she worked at the University of Massachusetts Medical Center, Dartmouth Hitchcock Medical Center, and Exeter Hospital. Since 1995, she has studied with leaders in energy medicine and medical intuition. In 2008, Hilary opened her office as a Natural Health Intuitive at the integrative & general family medical center, Whole Life Health Care in Portsmouth, New Hampshire. With clients referred by surgeons, nurses, physicians, psychotherapists, acupuncturists, physical therapists, nutritionists, and other holistic medical practitioners, Hilary uses energy medicine techniques to identify root issues of disease and stress. Hilary's hands-on work involves balancing and interpreting the subtle energy field of the human body to bring wellness and authentic health to her clients. She teaches on topics of energy medicine and health throughout the United States. Hilary is a graduate of Syracuse University and lives with her husband and two sons in New Hampshire. Core purpose/passion : To continue doing what I'm doing. To get the message to the healthcare world, that if we can take back the instinctive connection between patient and health provider, that energy of care, sharing, and the love of the healing arts, this would revolutionize the conversation around how we heal and how the healthcare system can restore the heart and soul of itself.  Website | Facebook | Instagram | Twitter  | LinkedIn  |   About Dr. M (Manon Bolliger), ND: Dr. Manon is a Naturopathic Doctor, the Founder of Bowen College, an International Speaker, she did a TEDx talk "Your Body is Smarter Than You Think. Why Aren't You Listening?"  in Jan 2021, and is the author of Amazon best-selling books "What Patient's Don't Say if Doctors Don't Ask". & "A Healer in Every Household" For more great information to go to her weekly blog:  http://bowencollege.com/blog.  For tips on health & healing go to: https://www.drmanonbolliger.com/tips   About The Healers Café: Dr. Manon's show is the #1 show for medical practitioners and holistic healers to have heart to heart conversations about their day to day lives.   Follow Dr. Manon, ND on social media! Facebook | Instagram |  LinkedIn  |  YouTube  |  Twitter | Linktr.ee |

In this episode, Russell talks about his career in the field of ADHD, and his involvement in a task force seeking to address ADHD, Inattentive Subtype, a separate disorder other than ADHD itself. He discusses Sluggish Cognitive Tempo, and the hypoactive nature, which is very different from the hyperactive and impairment in impulsivity. Russell explains that rather than being overly engaged with the environment, children, adolescents, and adults with SCT are disengaged from the environment, and often find themselves preoccupied with internal thought and experience. He discusses his experience helping families and children with ADHD, and his new book, 12 Principals for Raising a Child with ADHD. Russell Barkley, Ph.D. is the author of 12 Principals for Raising a Child with ADHD among several other works about ADHD and defiance in children and adolescents, and ADHD adults. Dr. Barkley retired as a Professor of Psychiatry and Neurology from the University of Massachusetts Medical Center and subsequently worked as a Professor of Psychiatry and Health Sciences at the Medical University of South Carolina. He is currently a Clinical Professor of Psychiatry at Virginia Commonwealth University Medical Center. Dr. Barkley continues to lecture widely and develop continuing education courses for professionals on ADHD and related disorders, as well as consult on research projects, edit The ADHD Report, and write books, reviews, and research articles.

CDC Proclaims Racism Public Health Crisis, Calls for Health Equity A new mandate out of the Centers for Disease Control & Prevention has asserted systemic racism as a public health crisis, a step the agency says will build the foundation to improve health equity. The statement from CDC’s director Rochelle P. Walensky, MD, MPH, acknowledged the racial health disparities seen in traditionally marginalized communities, including the Black, Latinx, and American Indian/Alaska Native (AI/AN) populations. “Yet, the disparities seen over the past year were not a result of COVID-19,” Walensky said in the written statement. “Instead, the pandemic illuminated inequities that have existed for generations and revealed for all of America a known, but often unaddressed, epidemic impacting public health: racism.” Guests:  Yele Aluko, MD, MBA Chief Medical Officer EY Americas Dr. Yele Aluko is the chief medical officer in EY Americas Business Consulting Health Sector. He is a proven physician executive and leader, with 25 years of clinical and administrative health system experience prior to joining Ernst & Young LLP in 2016. He advises health system clients on strategy, business and clinical operations providing C-Suite executives insight on health industry megatrends and enterprise growth opportunities. He is a member of the EY COVID-19 Pandemic Response Team where he advises EY leadership on return-to-workplace strategies that prioritize the health and safety of its employees. As a member of the EY COVID-19 Enterprise Resiliency Team, he provides client insight on return-to-work strategies and solutions designed to preserve workforce well-being and safety during and in the aftermath of COVID-19. He is a leader in the development of the EY Point of View on Health Equity and has designed solutions for clients seeking competencies relevant to elimination of health disparities and achieving health equity. As chief medical officer, he is a leader within EY physician enterprise operations and clinical integration practice where he assists health care system clients in physician engagement and alignment, provider accountability for value delivery, and defining and maximizing physician enterprise value for health care systems. He has supported organizations as they transition to integrated service line models of care delivery and recognizes the medical group’s impact on driving clinical quality initiatives. He is a former structural heart cardiologist and senior vice president of heart and vascular services at a 15-hospital integrated regional health care system in the southeast USA. His responsibilities included governance of an enterprise-wide clinical strategy overseeing cardiovascular service line vision, growth, clinical integration, physician alignment and standardization of clinical, operational and business processes. He obtained his doctor of medicine from the University College Hospital, Nigeria. He trained in internal medicine and cardiology at the College of Physicians and Surgeons of Columbia University and in invasive and interventional cardiology at Cornell University and University of Massachusetts Medical Center. He is board certified by the Canadian Board of Internal Medicine and is triple-board certified in internal medicine, cardiology and interventional cardiology by the American Board of Internal Medicine. Gil Bashe Managing Partner, Global Health Finn Partners Gil Bashe’s healthcare career spans the patient, physician, provider, payer and policy sectors. At the center of Gil’s life and work is the belief that communication is part of the care. As managing partner of Finn Partners Global Health, he champions the talent and ideas of the nation’s “Healthcare Agency of the Year” (Holmes Report). Prior to joining Finn Partners, Gil was Executive Vice President and Health Practice Head at Makovsky and Hill & Knowlton. During his tenure, he took on some of the health sector’s most vexing reimbursement and access challenges. As a result, he was named by PRNews as one of the nation’s “Top Crisis Communicators” and inducted into its Hall of Fame. Gil is passionate about public health in everything he does. He serves on the NHLBI GENTAC Working Group examining how genetics impacts cardiovascular disease and the health/tech advisory committee for mHealth Israel. He is immediate past chair of the American Heart Association Northeast Founder’s Affiliate. Gil is also an advisory board member of the Prix Galien Foundation, referred to as the Nobel Prize for health innovation. Gil is a past national board member of the Leukemia and Lymphoma Society and American Academy of Pain Medicine Foundation. Always ready to share knowledge, Gil is a columnist for PM360 magazine, speaker on patient advocacy and health communications and co-editor of the book Branding Health Services: Defining Yourself in the Marketplace. See omnystudio.com/listener for privacy information.

In this episode, we invite the Author of The Power of Energy Medicine, Hilary Crowley, to discuss the language of the energy body through the chakras. Tune in for an insider's look at how the body communicates through the language of the chakras, and dive deep into chakras, shadows, and how the body heals beyond words. Uncover the power of using energy as medicine and the body's extraordinary healing intelligence.  Hilary Crowley is the author of The Power of Energy Medicine: Your Natural Prescription for Resilient Health, a book released in 2021 through Skyhorse Publishing (New York, NY) with Simon & Schuster.  Hilary discovered the healing arts as the grandchild of three doctors. In her early career, she worked at the University of Massachusetts Medical Center, Dartmouth Hitchcock Medical Center, and Exeter Hospital. Since 1995, she has studied with leaders in energy medicine and medical intuition. In 2008, Hilary opened her office as a Natural Health Intuitive at an integrative family medicine practice, Whole Life Health Care in Portsmouth, New Hampshire. With clients recommended by surgeons, nurses, physicians, psychotherapists, acupuncturists, physical therapists, nutritionists, and other holistic medical practitioners, Hilary uses energy medicine techniques to identify root issues of illness and stress. Her hands-on work involves balancing and interpreting the subtle energy field of the human body to bring wellness and authentic health to her clients. Hilary teaches on topics of energy medicine and holistic health. She is a graduate of Syracuse University and lives with her husband and two sons in New England.   KEY POINTS / MAIN TAKEAWAYS: What is Energy Medicine?   What is Clairsentience? How do you enhance your ability to connect? An introduction to the Seven Chakras. How to identify blockages in your chakras. Ways to unblock your chakras.   QUOTABLES: “Honesty is extremely powerful. And this is my dream job of actually getting back in front of the doctors and the nurses and telling them to take back that initial impulse they have to heal and to help others. Because that is the most honest thread in the human experience, which is to help others.” “There's so much more than skin that holds me together.” “If you're looking for your guardian angel, your body is your angel.” “What if heaven is the moment that you realize that you would do this all over again?”   PRODUCTS / RESOURCES: Follow Hilary Crowley on Instagram @hilary_crowley_ - https://www.instagram.com/hilary_crowley_/?hl=en Her 9 steps “Power of Intuition” online class is available at hilarycrowley.com Her book, The Power of Energy Medicine, is available in bookstores everywhere through Simon & Schuster.  Tune in to The Good Energy Healing Show: Apple Podcasts: https://podcasts.apple.com/us/podcast/the-good-energy-healing-show/id1473955614 Spotify: https://open.spotify.com/show/5XfnaXUJbS1RiDAgiZrX1Q   Follow Dr. Jen Haley on Instagram @drjenhaley - https://www.instagram.com/drjenhaley Visit her website at http://www.drjenhaley.com Book a consultation with Dr. Haley here: https://dermoncall.net/jhaley   Radical Roots has the most purely sourced Chinese herbs and CBD tinctures to address your wellness needs.  To receive a 20% discount and try them out, go to https://radicalrootsherbs.com/ref/Jen%20Haley    BiOptimizers formulates amazing magnesium and gut supplements. Their magnesium supplement is the most potent, complete, and full-spectrum magnesium on the market.  It is the perfect addition to a healthy lifestyle to achieve clear skin, enhanced mood, energy, better sleep, and faster recovery.   Use code ”DRJENHALEY10” for 10% off at the checkout. Visit the website to show now: https://bioptimizers.com   Here is the link for Dr. Haley's favorite skin, hair, and nail supplements: https://www.purerxo.com/drjenhaley/rxo/company/my_recommendations.asp   MUDWTR™ is a coffee alternative consisting of organic ingredients lauded by cultures old and young for their health and performance benefits. With 1/7th the caffeine of coffee, mud gives you natural energy, focus and more without the jitters and crash. Check it out here: https://mudwtr.com/collections/shop?rfsn=5360767.64f734&utm_source=refersion&utm_medium=affiliate&utm_campaign=5360767.64f734  Radiance Revealed is edited by Instapodcasts (visit at www.instapodcasts.com)   

Do you feel intimidated by the words meditation or mindfulness but realize that practicing mindfulness may help you? Do you want to better manage your stress? In this episode, I interview one of my mindfulness gurus, Dr. Chris Chroniak, someone who taught me how to go deeper with my meditation practice. My goal with this conversation is to help you learn how mindfulness can lead you on a path of ultimate fulfillment and help answer questions you may have around meditation. And at the end, Dr. Chroniak provides a helpful meditation tool you can use during any stressful moment to calm your mind and body.Dr. Chris ChroniakChris Chroniak is a licensed clinical psychologist with 37 years of clinical experience. He received his doctorate in Counseling Psychology from Loyola University of Chicago. Dr. Chroniak specializes in integrating mindfulness into his work as an individual and couples therapist. He has completed advanced training in Mindfulness-Based Stress Reduction (MBSR) at the University of Massachusetts Medical Center, as well as Yoga Chicago's yoga teacher's training program. Dr. Chroniak is one of the most experienced and active MBSR instructors in the Midwest Region. He has taught the MBSR Program and the Graduate MBSR Program for the past 25 years in hospitals, clinics, corporate settings, and other locations throughout the Chicagoland area.Dr. Chroniak's practice: The Insight CenterYou'll LearnWhat mindfulness meansHow meditation leads to mindfulnessWhy mindfulness is so powerful to unlock your lifeWhy chronic stress creates inflammation that can lead to disease in the bodyWhat are the four components of holistic wellnessHow the body uses resources when stressed that prevents the body from building muscle or losing boy fatHow we can live in constant stress but are unable to notice itWhy there is no separation from the mind and bodyWhat are the components of a Mindfulness-Based Stress Reduction programWhy you have to get out of auto-pilot to begin living a fulfilled lifeResourcesWorry: Hope and Help for a Common Condition by Edward M. Hallowell, MDMindfulness-Based Stress Reduction (MBSR)Want to learn more about Cory's experience in Dr. Chroniak's MBSR program? Click here to email him and he will reach out to provide feedback if it makes sense.Connect with CoryBe sure to like my Facebook page @CoryCalvinOfficial to watch the live (video) podcast recordings and to receive updates on inspirational books and online courses I am creating. Become a member of my tribe.... www.corycalvin.com/tribe

Parenting is challenging. Some of the challenges—like effective disciplining and present moment awareness—are ubiquitous to parenting. No matter who you or your kids are, moments and experiences will test your patience and your wisdom. But while no parent has it easy, parenting children with special needs, neurodiversity, or mental or physical health issues comes with unique, extraordinarily trying experiences, and big questions to which it can be hard to find reliable answers. In this episode of Psychologists Off the Clock, Yael talks with Dr. Russell Barkley, an international authority on ADHD. Russ is also author of many books, including the bestselling Taking Charge of ADHD and his recently released 12 Principles for Raising a Child with ADHD. Using principles from his books and decades of research, Russ takes on questions Yael collected from friends, family, and peers about parenting children with ADHD. Join us to hear in-depth and reliable answers to our most pressing questions about how to raise neurodiverse children! Listen and Learn: The seven executive functions and how they're impacted by ADHD Russ' expert, in-depth answers to your questions about parenting and loving people with ADHD! What ADHD is and why the label can be misleading About some misconceptions parents often have about ADHD How to better parent a child with ADHD How to be compassionate towards yourself and your child as you parent Key differences in behavioral markers of ADHD and Oppositional Defiant Disorder (ODD) About the long-term data on medication for children How to find, appreciate, and reinforce strengths that show up in neurodiverse children Effective parenting and discipline strategies for children with ADHD Russ' hopes for his legacy, and the future of ADHD Resources Discussed on this Podcast Episode: Dr. Barkley's book, 12 Principles for Raising a Child with ADHDFind some of Dr. Barkley's lectures on his websiteFind other interviews with and lectures by Dr. Barkley on YouTubeEmily Perl Kingsley's poem, Welcome to HollandJon Kabat Zinn's book, Everyday Blessings: The Inner Work of Mindful ParentingAlison Gopnik's book, The Gardener and the Carpenter About Dr. Russell Barkley: Russell A. Barkley, Ph.D., is an internationally recognized authority on attention deficit hyperactivity disorder (ADHD or ADD) in children and adults who has dedicated his career to widely disseminating science-based information about ADHD. Dr. Barkley retired as a Professor of Psychiatry and Neurology from the University of Massachusetts Medical Center (1985-2002) and subsequently worked as a Professor of Psychiatry and Health Sciences at the Medical University of South Carolina (2003-2016). He is currently a Clinical Professor of Psychiatry at Virginia Commonwealth University Medical Center (2016-present). In semi-retirement, he continues to lecture widely and develop continuing education courses for professionals on ADHD and related disorders, as well as consult on research projects, edit The ADHD Report, and write books, reviews, and research articles. Related Podcast Episodes: Episode 14. Mindful ParentingEpisode 48. Practical Wisdom with Dr. Barry SchwartzEpisode 123. Tantrum Survival Guide with Dr. Schrag HershbergEpisode 149. How Not To Lose It with Your Kids with Dr. Carla NaumburgEpisode 161: The Gift of Failure with Jessica Lahey Learn more about your ad choices. Visit megaphone.fm/adchoices

Airing originally on January 28, 2021 on WYXR 91.7 FM in Memphis, TN, this episode of Faithfully Memphis features the Rev. Dr. Jesse Abell, Priest-In-Charge of All Saints Episcopal Church in Memphis, TN, in conversation with Dr. Deborah Harmon Hines. Dr. Hines is the retired professor and Vice Provost of the University of Massachusetts Medical Center. She was the first female lay president of the Union of Black Episcopalians. Dr. Hines currently lives in Memphis with her husband, the Reverend John Edgar Freeman. http://www.allsaintsmemphis.org/ https://www.ube.org/ Featured Music: "Higher Ground" by Stevie Wonder "Center of My Joy" by Richard Smallwood

Watch the full video at: https://www.youtube.com/watch?v=b_ni2Pm9u6c&t=1s  Watch clips of this episode at: https://youtube.com/channel/UCJmxuLG53h4YpEntf3SSt_g Enjoy this episode on pediatric femur fractures w/ Dr. Heffernan! He serves as Director of the Children’s Hospital Pediatric Orthopedic Surgery Fellowship Program and leads our research team in the Department of Pediatric Orthopedics. He also serves on several national committees through the Pediatric Orthopedic Society of North America, the American Academy of Pediatrics and the Scoliosis Research Society. Dr. Heffernan received his medical degree from the University of Pittsburgh School of Medicine and completed his residency training at the University of Massachusetts Medical Center. Dr. Heffernan then completed a fellowship in Pediatric Orthopedics and Scoliosis Surgery at Children’s Hospital Los Angeles

This month on Episode 18 of the Discover CircRes podcast, host Cindy St. Hilaire highlights four featured articles from the October 23 and November 6 issues of Circulation Research. This episode features an in-depth conversation with Drs Eric Boilard from the Université Laval in Quebec, Canada, and Fadila Guessous from Mohammed VI University of Health Sciences in Casablanca, Morocco regarding their study titled Platelets Can Associate with SARS-Cov-2 RNA and Are Hyperactivated in COVID-19.   Article highlights:   Feng , et al. No Contribution of EMPs to Endothelium   Lin, et al. Step Count and Predicted CVD Risk   González-Hernández, et al; Sox17 in Developmental Coronary Arteriogenesis   Khawaja, et al; HIV Antiretrovirals Alter Endothelial Activation     Dr Cindy St. Hilaire:        Hi, welcome to Discover CircRes, the podcast of the American Heart Association's Journal, Circulation Research. I'm your host, Dr Cindy St. Hilaire from the Vascular Medicine Institute at the University of Pittsburgh and today, I'll be highlighting four articles selected from the late October and early November issues of Circ Res. Dr Milka Koupenova, who is a platelet expert at the University of Massachusetts Medical School, will join me to interview Drs. Eric Boilard from the Université Laval in Quebec, Canada, and Fadila Guessous from Mohammed VI University of Health Sciences in Casablanca, Morocco. They're here to discuss their study, Platelets Can Associate with SARS-CoV-2 RNA and are Hyperactivated in COVID-19. Dr Cindy St. Hilaire:        The first article I want to share is titled No Evidence for Erythro-Myeloid Progenitor-Derived Vascular Endothelial Cells in Multiple Organs. The first authors are Teng Feng and Zibei Gao, and the corresponding author is Hui Zhang from ShanghaiTech University in Shanghai, China. Dr Cindy St. Hilaire:        In the early stages of mammalian embryogenesis, a population of cells called mesoderm-derived angioblasts, gave rise to self-renewing intraembryonic endothelial cells, that go on to populate the entire vasculature of the growing fetus. Recent studies have suggested that there is an additional embryonic source of vascular endothelial cells  that is derived from erythro-myeloid progenitor cells, also called EMPs, that are found in organs such as the liver, the lung, the heart, and the hindbrain. Dr Cindy St. Hilaire:        Evidence of an EMP cell source for vascular endothelial cells stemmed from the use of mirroring cell lineage tracking models. However, the authors of this study argue that these former conclusions were based on flawed genetic tools. To mark erythro-myeloid progenitor cells, the initial study had used a set of supposedly EMP-specific transgenes. However, transgenes are notoriously leaky, meaning, that cells other than EMPs may have been marked. To more accurately mark EMP derived cells, this study used a reporter that they integrated into the endogenous loci of a gene, CSFR1, which is specifically expressed in EMPs. Using this model, they failed to find any evidence of EMP derived vascular endothelial cells in any organ, thus they consider it unlikely that EMPs give rise to vascular endothelial cells. Knowing the true origin of vascular endothelial cells is essential, as it informs the design, development of treatments, and regenerative medicine approaches for vascular diseases. Dr Cindy St. Hilaire:        The second article I want to highlight is titled Association of Habitual Physical Activity with Cardiovascular Disease Risk. First author is Mayank Sardana and the corresponding author is Honghuang Lin, and they're at Boston University School of Medicine. Everybody knows that exercise is very good for overall cardiovascular health and current government guidelines suggest a minimum of 150 minutes of moderate to vigorous exercise per week is necessary to keep hearts healthy. There's an ever-growing interest in the use of smart watches and fitness trackers to assess an individual's activity, and many people believe that 10,000 steps a day is a good health goal. However, it's unknown whether the data obtained from smartwatches actually aligns with cardiovascular health prediction. Dr Cindy St. Hilaire:        To address this gap, this study recruited participants from the Framingham Heart Study to wear Apple smart watches for a month. The participants had also undergone a 10 year atherosclerotic cardiovascular disease risk assessment based on their age, sex, cholesterol levels, blood pressure, diabetes diagnosis, and smoking history. The step count and activity data from 903 participants found that for every 1,000 average daily step increases, there was an associated 0.18% reduction in predicted cardiovascular disease risk. This association was weaker but still significant after adjusting for body mass indices. The authors conclude that like other measures of activity, those recorded by smart watches are correlated with better cardiovascular health. Dr Cindy St. Hilaire:        The third article I want to share is titled, SOX17 Controls Emergence and Remodeling of Nestin-Expressing Coronary Vessels. The first author is Sara González-Hernández and the corresponding author is Joan Isern, and they're from Centro Nacional de Investigaciones Cardiovasculares in Madrid, Spain. The exact signals and mechanisms that regulate coronary vascular development are not fully characterized, yet defining these pathways could provide valuable insights into both life threatening congenital coronary abnormalities as well as the neovascularization process that occurs after myocardial injury. To examine coronary vasculature development in more detail, this team created a transgenic reporter system, which used an enhancer region within the Nestin gene to specifically label mouse coronary artery endothelial cells. Dr Cindy St. Hilaire:        Cells were isolated from developing embryos at stages of vessel sprouting and vessel remodeling, embryonic days 13.5 and 17.5 respectively. And transcriptional differences were assessed between coronary and endocardial endothelial cells. They found that the transcription factor SOX17 was more highly expressed in these coronary endothelial cells compared with the endocardial endothelial cells, and that expression of SOX17 increased between these two time points that hearts were collected. Coronary specific deletion of SOX17 in genetically engineered mice lead to severe defects in arterial remodeling, confirming the transcription factor's role in coronary vessel development. The team suggested that perhaps SOX17 could be a future therapeutic target for conditions, where promoting coronary artery regeneration or remodeling might be of clinical benefit. Dr Cindy St. Hilaire:        The last article I want to share with you before we switch to our interview is titled, HIV Antivirals Affect Endothelial Activation and Endothelial-Platelet Crosstalk. The first author is Akif Khawaja, and the corresponding author is Michael Emerson from the Imperial College, London. Infection with HIV is not the death sentence that it once was. With a regime of continuous anti-retroviral medications, the disease can be managed for the long term. Now that people with HIV are living longer, it is clear that they are at a greater risk of developing cardiovascular disease, possibly due to the off-target effects of these drugs. One HIV treatment, Abacavir Sulfate or ABC, was found to cause a 90% increase in the relative risk of myocardial infarction.  ABC has been proposed to cause endothelial dysfunction, however a mechanism by which this may occur has not been established. To see if anti-retrovirals effect endothelial cell function, this group tested three drugs; ABC, as well as tenofovir alafenamide or tenofovir disoproxil fumarate, TAF and TDF respectively, on human endothelial cells in culture. Dr Cindy St. Hilaire:        They found that treatment with ABC, but not TDF or TAF, caused endothelial cells to produce more cell adhesion protein, ICAM-1, and also tissue factor, both of which promote blood clotting. Endothelial-derived microparticles, or EMPs, are a biomarker of vascular dysfunction, and these were produced in the ABC treated cells, not in the TDF or TAF treated cells. These EMPs also promoted the increase of ICAM-1 and tissue factor expression, as well as the activation of platelets which can induce blood clotting. These results suggest that altering HIV treatments to avoid or minimize endothelial damage could help to reduce the cardiovascular disease risk in HIV patients. Dr Cindy St. Hilaire:        Today, I'm excited to have with me Drs. Eric Boilard from Université Laval in Quebec, Canada, Fadila Guessous from Mohammed VI University of Health Sciences in Casablanca, Morocco, and they are here to discuss their study, Platelets Can Associate with SARS-Cov-2 RNA and Are Hyperactivated in COVID-19. Also, with me today is Dr Milka Koupenova from the University of Massachusetts Medical Center in Worcester Mass, and she's an expert on platelet virus interactions, and she also wrote the editorial that's accompanying this article in our November 6th issue. So thank you, everyone, for joining me today. Dr Eric Boilard:                Thank you for inviting us. I look forward to reading the editorial. Dr Milka Koupenova:     I hope you like it Eric. Dr Cindy St. Hilaire:        Yeah, we're spanning a lot of time zones and we're actually having a little bit of technical difficulties so hopefully Fadila is going to be able to pop in. We can certainly see her on our Zoom call right now. But with that, we're many months into this pandemic now and it is blatantly clear that COVID does not just present with pulmonary symptoms. Many organ systems can be affected, such as the circulatory and neurological systems, but one thing that connects all the parts of the body is the blood system, and before we get into the details of the study, I would love to hear how this collaboration between Quebec and Morocco happened. And then, could you summarize the major findings? Dr Eric Boilard:                We both, in Morocco and in Quebec, we had pretty much the same working hypothesis that platelets may be contributing to the overwhelming inflammation in COVID-19 and why. As you know, in Morocco the pandemic hit before us in Canada, and they had a committee that studied patient samples and studies were going on. Whereas us in Quebec, in fact to be frank, in Quebec City, we didn't really have the first wave even. So we were very excited to evaluate our hypothesis but we had no clues other than the actual virus. We actually were working with the virus and human platelets from healthy individuals, but no samples from patients. Clinicians in Morocco were very willing to contribute and to perform working on patients so that's how Younes Zaid, the first author of the manuscript, and Fadila then contacted us given our past work on platelets and viruses and the collaboration was initiated. Dr Cindy St. Hilaire:        That's wonderful. I love hearing about these multi-institute collaborations. Team science is really the future. I think it really elevates everything. Dr Eric Boilard:                Despite the fact that the distance and I mean, it was through Zoom, but we've been doing weekly meetings with the two labs since March. Dr Cindy St. Hilaire:        So, can you maybe give us a quick summary of the major findings of your study? Then we'll dig into the details of it. Dr Eric Boilard:                Sure. When we actually started the work, what we knew about COVID-19 was that the severity was likely due to the overwhelming inflammation due maybe to a cytokine storm, so we knew that. It was reported that patients with COVID-19 had a lower platelet count and although thrombocytopenia in the patients was very mild or modest, and did not require transfusion, at that time, our hypothesis was that platelets could contribute to inflammation and therefore could release cytokines and other molecules from their granules in COVID-19. So it's only a couple of weeks after that became more of use that thrombosis and cardiovascular manifestations could also contribute to morbidity and mortality. Dr Eric Boilard:                Our design was to look at platelet activation in vitro. So there were studies where we performed aggregation assays with platelets from COVID-19 patients, some were severe and non-severe. There were assays where we actually evaluated a number of molecules and plasma from the patients. We looked at granular components, like PF4 and serotonin, that were greatly increased in COVID-19, both in non-severe and severe patients. We looked at vesicles, or microparticles, released from platelets that were also increased, and cytokines. We look at up to 42 cytokines, if I remember well, in the plasma of the patients and we also look at these cytokines in the platelets from the patients and we found less cytokines in the platelets when there was inflammations, which may suggest that platelets have released their cytokine cargo. I mentioned that platelets were hyperactivated so they bound better on collagen and they aggregated faster with suboptimal concentration of thrombin. Dr Milka Koupenova:     I find this dysregulation of cytokines in the platelets specifically very interesting and the fact perhaps that you see that certain cytokines are decreased in platelets and increased in plasma, basically can suggest that maybe platelets are the ones that are contributing to the overall cytokine storm, as you said. My question for you is, what do you think is the contribution of platelets to the dysregulated immune cell response in immune cell activation during this particular infection? Dr Eric Boilard:                That's a good question. There are studies that show that platelets could interact with leukocytes. The leukocytes migrate to organs through lungs in this case, so one possibility is that molecules derive from platelets and cytokines but also their interaction with leukocytes could further promote their migration to lungs or adhesion to vasculature. There are studies that suggest that NETs form in COVID-19 and could contribute thrombosis and NETs can implicate interaction between platelets and neutrophils. Or molecules derived from platelets that are neutrophils so these might be some of their contributions. Dr Milka Koupenova:     You are reporting changes of IL-7 in platelets which is particularly interesting because they're responsible for T and B cell development and activation. I was wondering if you could comment on that particular fact and how that may be practically responsible for these responses in these patients that come and present with symptoms. Dr Eric Boilard:                Yeah, it's a good question. If we look at the different cytokines that were in platelets, we found that many were reduced. That pointed to their release in COVID-19 and some we had expected, such as some broad factors and there was TGF, CD40 ligands inside the cytokine but we expect that its stored in platelets that was released. That made sense to us. IL7, like you said, it was not really reported in platelets and when we look at the 40... broad area of cytokines using the multiplex, that increased in platelets during COVID-19. So this one was increased. Does it mean that platelets translated but some of it is released but some remain in platelets? We have no explanation for this. Does it impact lymphocytes or B cells? Dr Fadila Guessous:        If we go further and in terms of seeing the front they know what was downstream, IL7 production in general does not look like for psychometry, what happens to B cells and T cells in our complex. So we just look at the panel of the 48 cytokines, but we didn't go really further. Dr Cindy St. Hilaire:        I kind of have a little bit of a more basic question regarding cytokines and where they're coming from. I'm going to guess it's definitely not known for COVID but in maybe any viral infection that can lead to a cytokine storm, is it known what the relative contributions of cytokines are from the platelets, from the leukocytes, and from inflammatory cells? Is there any evidence of which is the bigger player? I mean I know all the different camps have ideas, but has anyone looked at that? Dr Fadila Guessous:        We were talking about this actually with Eric. If I had to rephrase your question, like what's the starting point, right in terms of cytokine storms?   Dr Fadila Guessous:        We don't know. We don't know because when it started in China, everyone was talking about the big cytokine storm. Everyone was talking about monocytes, about neutrophils, so on and so forth but the platelets we were just saying there was thromboembolism in the lungs, right? But no one was talking about cytokine production by the platelets. I think we were the first ones, Eric please correct me if I'm mistaken, we were the first ones to show, when we started, to show that there was the cytokine release by platelets. How big of the extent of the contribution of platelets to the cytokine storm, we don't know, but we have to figure out first what's the key player? The first one to respond, right? Dr Cindy St. Hilaire:        Lots of projects. Dr Fadila Guessous:        Well the big question, actually we have this big contribution in terms of the cytokine release and activation of platelets, but is it the starting point? We don't know. Dr Cindy St. Hilaire:        I guess related to that, you noted that you saw very little ACE2 expression in the platelets which most people appreciate is the entry mechanism of the virus into the platelets. Can you discuss that a little bit more, maybe explain it a little bit more and what that might mean? Your findings versus what other people have seen versus potential other means of entry? Dr Eric Boilard:                Yeah sure. As you mentioned, ACE2 is the putative receptor for the virus so that made sense to us to examine whether the receptor may be expressed by platelets. I don't think we mentioned it but we found that there were some... at least for some patients there were SARS-CoV-2 RNA associated with platelets and that's why in part we look at ACE2 RNA expression by platelets. It seems simple but it wasn't that simple. We were actually using through PCR and different approaches and primers we got different answers using intron-spanning and non-intron-spanning primers from that, the receptor was presented so that in fact we ended up concluding that there was little or no ACE2 RNA in platelets of COVID-19 individuals that we examined but that there was some DNA that could be contaminating, potentially due to extracellular DNA maybe provided by extracellular vesicles[inaudible 00:19:30] or something but either way we're speculating. Dr Eric Boilard:                One intriguing aspect of the study is that the SARS-CoV-2 RNA was not found on platelets from every patient, it was only in 20% of them and we unfortunately were not able to look at the RNA of these positive patients to determine whether these patients were positive for ACE2 RNA and potentially in some donor cells in some patients, there might be some levels of expression and we are not excluding this. Dr Eric Boilard:                So yeah, you ask whether it was consistent with other studies? There was the study by Manny that was published, in Blood where they also could not find the receptor but our studies contrast with the one that was more recently reported by Zhang in Journal Of Hematology & Oncology. In this study they found in fact that a robust expression of ACE2, both protein and RNA, and it was both in humans and mouse so clearly there's still work to do to determine whether ACE2 is present or not, but there could be other means of interaction between the SARS-CoV-2 and platelets if there is indeed an interaction. We speculated that maybe in some patients there could be antibodies against other coronaviruses, you know the cold, the viruses that give the minor cold symptoms and that in some of the patients these cross-reacting antibodies could promote the interaction with platelets through their receptor for IgG , that could be a means. Dr Eric Boilard:                There are other receptors that are expressed by platelets, there's probably several. I'm sure we have a list, but one could be the CD147. It's a receptor that is known to be expressed by platelets and that was suggested to interact with SARS-CoV-2, at least it does interact with SARS-CoV, the first one, CoV-1. So these are potential candidates. So there's work to do. Dr Fadila Guessous:        What we found was that in Eric's lab, that you have this 20% of aged people that have this SARS-CoV RNA in place, in 20% of aged people. So should we look only at aged people for this ACE2? If they have the receptor for ACE2, maybe? It's like 20%, only aged. And this 20% of people we investigated, they were only aged. Not other people. So do we... probably, we have to go further and investigate more of this age group for ACE2. . Dr Milka Koupenova:     So if I can make a comment, despite the fact if ACE2 was expressed or not, right? Could it explain the profound thrombotic response that you see? What's your take on it? Dr Eric Boilard:                Personally, I doubt it. I think the disease starts in the lungs and this is where the damages are made, and that it may expand to blood vessels and then multiple players can then from a place of activation damages themself, the lack of O2 in some patients that are in ICU. And then of course the activation of the other cells, the cytokines themselves. So there are numerous ways I will say that can be to play for activation. In fact, the study by us, the one in Blood, they use plasma from the COVID-19 patient and I would assume there was no actual virus particle in this plasma. And they incubated it with platelets, and platelets were then activated. So there are molecules in COVID-19 that circulate in blood that can activate platelets, and that adds to the vasculature damage trauma. I would think that that could come from principle factors. Dr Milka Koupenova:     Which would explain why is it so dysregulated, which brings it to the next question now with a favorite question in the literature. Should we be using antiplatelet drugs? Your opinion, Eric and Fadila? Dr Fadila Guessous:        Well with my collaborator, Younes Zaid you know, and first author on this paper, actually they are going for that. They are having small trial giving antiplatelets treatment to a few patients in our lab. You will hear the story. I don't know if Eric will allow me to disclose this? I don't know because Younes is not here, but they are using heparin for now and for the treatment, but now they are trying antiplatelet treatment as a small trial. Dr Milka Koupenova:     So when do they give antiplatelet drugs? At what stage of the disease? Dr Cindy St. Hilaire:        I think maybe the way to ask the question is: If you were going to use antiplatelet therapy for changing the course of the disease, where do you think is the best time point within the disease, from the day you get infected to symptom presentation and well after that, what time point do you think it's most critical, the platelet function? Dr Fadila Guessous:        It's a good question. It's a good question because the trial is done in in our lab and I didn't have insight. What time is the time point. Honestly, I don't have an answer for that in time point. Because I have a... they started the trial- Dr Cindy St. Hilaire:        No, but I guess, based on what we know and what you've found in your study, where would you think it's more critical, if we even can speculate on that? Dr Fadila Guessous:        Yeah, the symptoms. I would give them from the beginning of the symptoms for me. Because otherwise, when you are in the cytokine storm and you have all this [thromboembolism in the lungs and everything, it's too late. Dr Eric Boilard:                And if I can add something. When we think of immune cells or B cells, D cells, we don't say anti-lymphocytes or anti-neutrophil therapy. But when we come to platelets, we think that the molecules that are known to impact some of the platelet activities, we think of aspirin, clopidogrel, coagulation, and we call it anti-platelets but. But platelets, I mean, they can do a lot independently of from vaccine, independently of EDP, and sometimes we forget that they are more than just these poor thrombotic cells and that there are different studies that has been published by different groups and us that found that you can use, for example, COX-1-deficient platelets. So they won't make thromboxane yet, they can make lot of IL1 and be pro inflammatory, although they will not make thromboxane. So we actually use mice where were we use a variety of anti-platelet therapies but yet their platelets were able to come out inflammation so there's no one drug that can get all the platelet functions at once, so it's important to remember that. Dr Cindy St. Hilaire:        It sounds like maybe some of them could possibly make things like a cytokine storm almost worse, if we're targeting the wrong anti-activity? Dr Eric Boilard:                All depends on how platelets are activated. Whether we are activating a GP pathway, or a nighttime pathway or both at the same time, and the environment where platelets are localized and activated so that they all back the response to this. Dr Cindy St. Hilaire:        So you're saying it's complicated. Dr Eric Boilard:                Yeah, I think it's not simple. Dr Milka Koupenova:     Anything complicated, it's platelets. So in a way I think that perhaps what we need to acknowledge is targeting platelets for whatever response. I completely agree that platelets should be targeted at one point but what drugs should be used, is the question? What specific receptor or what specific response? And if we manage to figure some form of controlling the inflammatory response, that specific, what you see, that huge amount of cytokine dysregulation that will be great. But if you're targeting platelet-specific function when it comes to thrombosis, I'm a bit concerned that there has to be an exact time in which that's important. And the reason why is because if you have this damage in the endothelium, as you see reproducing the virus in the endothelial cells, and if platelets are not doing their own function then perhaps a lot more virus is leaking into the circulation. And that could be why you see some patients that have it, some patients that don't have it, which is a question that I want to ask. Dr Milka Koupenova:     Why do you think some patients have it and some patients don't have it? And do you think that perhaps as the virus gets processed into a platelet and digested, we are missing a time point? Because we're not taking platelets from patients at the same time after infection. We have no way of doing that. So what is your take on the fact that you have virus in some platelets? And from your study, perhaps, if we rely on the numbers, the people who have more severe symptoms seem to have a little bit more. Correct me if I'm wrong. Dr Eric Boilard:                Actually, the older people have more chance of having it but it was not in the more severe people. In fact, even among the non-severe patients, there was 20% of them that had platelets with positive RNA. So that didn't correlate with severity or any outcomes. The only correlation we could identify was age. Dr Milka Koupenova:     So do you think that perhaps in older individuals there are problems would be degradation of the virus, and hence they are not initiating the proper response? Dr Eric Boilard:                Yeah, potentially. Maybe there's somehow an indication of the virus from the organs and it's a destination or it's not captured fast enough on the first varrier of the immune cells in the lungs. Right now we don't have the evidence that it's actually the virus that is in platelets, right? The RNA and there's still work to determine if the virus is there. Dr Milka Koupenova:      So practically, in summary, we don't know what it is. Although, I mean, with a bias, me probably like you, and you're very nice, you're cautious, but I also believe that the virus... and it's a belief. That the virus gets inside of platelets. Dr Fadila Guessous:        How, Milka? How? Dr Milka Koupenova:     There could be some issue that we don't see, and as Eric says, it's some form of an age factor. There could be other receptors. Platelets are tricky, they don't act like every regular cell so they may have evolved to have other receptors that maybe they are not as functional in the ither cells but they're platelet specific. There is the process that from all these cytokines perhaps, platelets are just sucking in things by micropinocytosis, which has happened. The thing that's important to think and mention is that if a virus is not going into a platelet by receptor-specific mechanism, perhaps it's locating to the wrong compartment, and then not introducing the proper immune response. Perhaps that's the reason of why you're catching it only in 20%. This is all very, very speculative. Dr Eric Boilard:                Yeah. And are you putting in a contribution of megakaryocytes] in the lungs where they will burst … Dr Milka Koupenova:     Yes. That it. Absolutely, it's quite possible. That's a collaboration then you should perhaps consider with Dr Craig Morrell. Which is very interesting, right? We don't know. We were never able to figure, even with our full studies, we also saw, what is it, four out of 18? So it's like 25% of the platelets had RNA for a flu but when you look what the antibody of the virus you find that a lot more platelets have it. So is it that we're missing some form of a process that the virus quickly gets digested and it initiates a response? I don't know until we get the right tools. But currently we are struggling with tools, practically, to assess that question. Dr Eric Boilard:                Yet it's impressive what's been done since March with the Covid. Dr Milka Koupenova:     Oh, some of them is good. Some of them is really important science and some of them is questionable that raises more questions. Dr Eric Boilard:                Absolutely, yeah. Dr Milka Koupenova       I personally think it's very important what your study is showing because it gives a base of truly thinking about how platelets maybe truly acting as an immune cell at the beginning. I know that Eric and I might be a little bit biased when it comes to that, but when does the thrombotic response stop? And when does the immune response stop of a platelet? And is it necessary to stop and to be all together? How do we push one and doesn't stop the other? These are the questions that we in the field truly need to assess and that's what I really like about your study, is that it raises these important questions. Dr Fadila Guessous:        Before the call, I was looking at the paper from University of Verona. I mean, I was hoping they will find more answers to the same question that is a favorite from University of Verona, and actually they are also more speculative. They didn't answer the question, the same questions we are asking. Dr Milka Koupenova:     Well, until we have the virus on hand, the actual virus, it's a little hard for us. And then the other point is even if you have the virus on hands, you're doing all of these in vitro studies, how do you assess the entire immune response? Can we think of platelets just as platelets without being in cells, right? What is your take on that, Eric or Fadila? Can you think of platelets just as platelets when it comes to mediating a response to a viral infection? Because we think okay we do this particular thing with platelets and then they mediate this and they mediate that, but perhaps the interaction between platelets and all the immune cells at the beginning of the response is super important. And I do struggle sometimes with the assessment of what amount is just platelets and what is the communication between each immune cell and platelet. It's very hypothetical. Dr Eric Boilard:                I agree that I see platelets as communicators to other cells. I mean, they're so numerous and there are bags with cytokines and other molecules and RNA and micro RNAs and it can impact for different organs, tissues, cells. The fact that they were activated, even in the non-severe patients, all the non-severe patients we analyzed, platelets were there, they were activated. So there was something going on, although thrombosis was not of use in these patients, so they made plates front row and the front part of the disease and the pathogen as a cell. Dr Milka Koupenova:     So is there a way of somehow, as you perceive in your future studies, to get platelets from people who get the virus but don't have any symptoms, and compare their cytokine profile of platelets to what you see? Because we focus so much on the people who get infected, logically, right? But truly to assess what is the difference, if we can figure why those patients are not having this profound response, right? Dr Eric Boilard:                Something that we dream of. The fact that collecting platelet from someone who has no symptoms is…Because we, if they have no symptoms, then they don't come to us. They don't stop- Dr Fadila Guessous:        They don't show up at the hospital. Dr Milka Koupenova:     And so you have to recruit them by tests, right? Because we screen, for instance, our institution screens. But it's hard, right? No one wants to take blood from a… Dr Fadila Guessous:        You get this kind of calls, people are asymptomatic, they don't have any symptom, they won't show up at the hospital. We used whatever we had in our recruitment from the hospital. Dr Eric Boilard:                In fact, you can maybe go through the transfusion work, the studies on transfusion where they actually collect blood from people and people sign that they have no symptoms when they do give blood. And there are studies from China and more recent ones in France where they then went back to this bags of... these were plasma, but maybe one could do it with platelet concentrates. And then go back to these bags where people had signed they had no symptoms when they gave blood, and screened platelets for RNA and then... but you have dozens of dozens of samples to test, but they are available. And maybe someone could find that many were positive but they were asymptomatic, using transfusion studies, maybe. But recruiting people from outside, asking we want people with no symptoms for… Dr Cindy St. Hilaire:        I know we're doing sentinal testing of our students, so. Somehow the group doing that needs to couple with platelets studies. But that was wonderful. Thank you Dr Boilard, Geussous, and Koupenova for joining me today. This has been an amazing interview. It's a wonderful study. Good luck on the future research and thank you for moving the field forward on this. Dr Eric Boilard:                 Thank you very much for inviting us. It was great and we are pleased to interact with you. Thank you. Dr Milka Koupenova:     Very nice to meet you Fadila, Eric. Dr Fadila Guessous:        Thank you so much for having us. It's really it's a pleasure to have this interview with you and of course I have to say that really it has been a wonderful collaboration with Eric and Younes in our lab. I am from Casablanca so we had really many people involved in this project and everyone, we worked really, really hard to get this very... I mean, you can see the time, it's from March to now, to get this paper out it was really a big effort. A big effort from the Moroccan side and from Eric's team in Quebec City and so we are really very pleased to have this wonderful collaboration. Thank you so much for having us. Dr Cindy St. Hilaire:        That's it for the highlights from the late October and early November issues of Circulation Research. Thank you for listening. Please check out the CircRes Facebook page and follow us on Twitter and Instagram with the handle @CircRes and #DiscoverCircRes. Thank you to our guests, Drs. Eric Boilard and Fadila Guessous, as well as Dr Milka Koupenova for co-hosting the interview with me. Dr Cindy St. Hilaire:        This podcast is produced by Rebecca McTavish and Ishara Ratnayaka, edited by Melissa Stoner, and supported by the editorial team of Circulation Research. Some of the copy text for the highlighted articles was provided by Ruth Williams. I'm your host, Dr Cindy St. Hilaire, and this is Discover CircRes, you're on-the-go source for the most exciting discoveries in basic cardiovascular research.  

Ross W. Greene is an American clinical child psychologist and New Your Times Best selling author of the books The Explosive Child, Lost at School, Lost & Found, and Raising Human Beings. Greene developed the model of intervention called Collaborative & Proactive Solutions (CPS). He has a Ph.D. in clinical psychology. Greene is founding director of the non-profit Lives in the Balance, and developed and executive produced the documentary film, The Kids We Lose. Greene's research has been widely published in academic journals, and he and the CPS model have been featured in popular media including The Oprah Show, Dateline NBC, the CBS Morning Show, the Public Broadcasting Service (PBS), National Public Radio, The Washington Post, Mother Jones magazine, and The Atlantic. Greene received his undergraduate degree at the University of Florida and his Ph.D. in clinical psychology at Virginia Tech in 1989. He completed his pre-doctoral internship at Children's National Medical Center in Washington, DC. His academic appointments include the Department of Psychology at Virginia Tech (1989-1991, 2012 to present), the Faculty of Science at University of Technology Sydney, Australia (2016 to present); the Department of Psychiatry at Harvard Medical School (1992 to 2013), the Departments of Psychiatry and Pediatrics at University of Massachusetts Medical Center (1991-1992); and the Department of Education at Tufts University (2010 to 2013). Though he originally called his model "Collaborative Problem Solving," he is not affiliated with those now marketing that product and does not endorse what they have done with his work.

Dawn King, MA, LPC, CACIII is a Licensed Professional Counselor and a Certified Addiction Counselor Level III. She has 20 years experience working in various settings and currently owns a private practice in Arvada, CO. She is a Qualified Mindfulness-Based Stress Reduction teacher . She completed her training through the Center for Mindfulness in Medicine, Health Care and Society at the University of Massachusetts Medical Center. Dawn specializes in addiction, anxiety disorders and stress management. She is passionate about helping busy professionals break free from unhelpful habits and the self-doubt that holds them back from achieving professional and personal success.https://dawnkinglpc.com/To learn more about Rob Lohman, visit www.TheAddictionRecoveryHub.com

THE BENEFITS OF MINDFULNESS MEDITATION In the past several decades science has started to look at mindfulness meditation as aserious form of medical treatment, at the very least as a complement to modern psychological treatments. Due to pioneers in the field of mindfulness meditation like Ellen Langer Ph.d. SocialPsychologist at Harvard, Jon Kabat- Zinn Ph.D. of Massachusetts Medical Center and Sara LazarNeuroscientist at Harvard University and their ongoing research and MBSR/MBCT programs, mindfulness practice is now becoming part of mainstream medicine

Dr. Sudha Seshadri is a Professor of Neurology at Boston University School of Medicine and a Senior Investigator at the Framingham Heart Study. She also serves as Co-Director of Medical Education for the Neurology Residency and Clerkship programs. Sudha’s work is a big part of who she is and her purpose in life, but when she’s not at work, she loves to read. She has been an eclectic reader, devouring everything from poetry, novels, and nonfiction, since she was a kid. Reading has been an escape, as well as a source of information and inspiration. Sudha occasionally writes her own poetry as well. In addition, she likes to spend her free time walking, trekking, going for short runs, and being a parent to her daughter. She divides her time at work between being a clinical neurologist who sees patients with memory problems and being a researcher. In her research, Sudha is trying to determine why the brain and cognitive function decline with age and what are the modifiable factors that determine this decline with the hope of better predicting and preventing it. Sudha attended medical school at the Christian Medical College of Madras University in India. Afterwards, Sudha completed residencies in Internal Medicine and Neurology at the All India Institute of Medical Sciences in New Delhi. Fellowship in the Neurobiology of Aging and Alzheimer Disease at the University of Massachusetts Medical Center. Sudha previously worked as an Assistant Professor of Neurology at the All India Institute of Medical Sciences. She also completed a residency in Neurology at Boston University School of Medicine and she joined the faculty at Boston University in 2001. Sudha is the recipient of the E. Merck Gold Medal in Neurology and Allied Sciences, the Jack Spivack Excellence in Neurosciences Research Award from Boston University, and she is also a Member of the Alpha Omega Alpha Medical Honors Society. Sudha joined us for an interview to discuss life, science, and medicine.

In this episode, we discuss what mindfulness is and why I believe it can be especially helpful for expats and others living abroad. I'll also give you some practical suggestions to get you started with practicing mindfulness in your daily life.  What you'll hear in today's episode: • What is mindfulness? (We'll discuss the different components of the definition and what each of these components really means.) • Some reasons why mindfulness may be especially helpful for expats and others living abroad. • Some basic tips for beginning to practice mindfulness and a suggestion for a mindfulness exercise for you to practice in your daily life. Resources mentioned in today’s episode: • General information about Jon Kabat-Zinn, founder of the Mindfulness-Based Stress Reduction (MBSR) program at the University of Massachusetts Medical Center. • Some more information about how do define mindfulness, provided by Jon Kabat-Zinn. • More information about how mindfulness can be helpful, including links to relevant research.

On the July 26, 2016 Boomer Generation Radio program, the guests are Dr. Diane Reibel, who directs the Stress Reduction Program at the Jefferson-Myrna Brind Center of Integrative Medicine at Jefferson Health; and Dr. Don Friedman, clinical associate professor of medicine at Kimmel Medical College at Thomas Jefferson University in Philadelphia. Diane Reibel, Ph.D. Diane Reibel, PhD, cofounded the Stress Reduction Program at the Jefferson-Myrna Brind Center of Integrative Medicine in 1996. She has taught mindfulness-based stress reduction programs for more than 16 years. Dr. Reibel has participated in professional training under the direction of Jon Kabat-Zinn, PhD, founder of the Stress Reduction Clinic at the University of Massachusetts Medical Center, and is certified as an MBSR teacher through UMass Center for Mindfulness. In addition, she is a research associate professor in the Department of Emergency Medicine at Jefferson, and studies the effects of mindfulness on physical and psychological health. Her research is published and widely cited in both scientific journals and the popular press. She is coauthor with Don McCown of Teaching Mindfulness: A Practical Guide for Clinicians and Educators. Dr. Reibel brings both a scientific foundation and wholeheartedness to her work.     Dr. Don Friedman Donald M. [...] The post BGR 7/26/16: Stress Reduction, Mindfulness, and Spirituality in Medicine and Health appeared first on Jewish Sacred Aging.

Join Shelly in a conversation with Mindfulness­based Stress Reduction (MBSR) facilitator and fellow painiac Cecily McGaw. M BSR and its curriculum integrates both seated and walking meditation, gentle movement, and simple body­awareness practices. T he MBSR program started in the Stress Reduction Clinic at the University of Massachusetts Medical Center in 1979 and is now offered in hundreds of hospitals and clinics around the world. MBSR is an inspiring tool for pain management because it emphasizes the need for a patient, practitioner partnership in healthcare. This approach allows the patient to tap into their own deepest inner resources for learning, growing, healing, and transformation, which ultimately can significantly empower people living with pain. Mindfulness has a hugely powerful impact on pain reduction. Researchers have found that mindfulness meditation reduces pain by activating the orbital frontal cortex and the anterior cingulate cortex, and these brain areas are associated with the self­-control of pain and mindfulness also helps to deactivate the thalamus, which is considered a filter, it determines which sensory information is sent to the higher centers of the brain. These new studies are showing that pain relief is actually going beyond the placebo effect. And because of this research we are now able to do imaging of the brain and we can actually see and track how the brain is changing as a result of these practices. Mindfulness can reduce pain levels in daily life and help you feel better equipped at handling flare­ups, challenging days, and difficult emotions that arise while living with pain, so that you can feel more like yourself and less like a patient. Although Shelly Jackson is a certified professional coach, she is not providing medical advice. The pain management information on Painiac the Podcast for Mindful Pain Management is provided by Peaceful Body Coaching solely for informational purposes as a public service to promote wellness, and to support people living with chronic pain. It is not meant to provide medical advice tailored to you in any way. It does not constitute medical advice and is not intended to be a substitute for proper medical care provided by a physician or other licensed healthcare practitioner. Shelly Jackson, Peaceful Body Coaching, and the guests on Painiac assume no responsibility for any circumstances arising out of the use, misuse, interpretation or application of any information shared on Painiac the Podcast for Mindful Pain Management. Always consult with your doctor or healthcare practitioner for appropriate examinations, treatment, testing, and care recommendations. Do not rely on information on this site as a tool for self-diagnosis. If you have a medical emergency, please call 911 Theme music provided by www.bensound.com

Special guest Greg Seward Director at University of Massachusetts Medical Center and School and certified Master Tobacco-Treatment Specialist joins the Take 12 Radio co-hosts on the topic of smoking, vaping and chewing. With the emphasis on Vaping and e-cigarettes this show is one you don't want to miss.

Are you present right now, at this very moment? Or is it difficult to stop the chatter and thinking? Can the practice of being present moment to moment change how I feel? Bob Stahl, Ph.d., MBSR teacher and author of the MBSR Workbook, joins us for part two of our conversation on mindfulness and the benefits of Mindfulness Based Stress Reduction (MBSR). MBSR is an intensive 8-week group program in which people learn and practice mindfulness meditation, mindful yoga, and mindfulness in daily life. The program was created by Dr. Jon Kabat-Zinn, of the University of Massachusetts Medical Center and has helped people gain tools, skills and experience in reducing stress and suffering. People all over the world are practicing MBSR in hospitals, schools, their homes, veteran centers, and even in the United States Congress, led by the efforts of one congressman from Ohio. You too can learn and access the benefits and resources through an Mindfulness Based Stress Reduction (MBSR course). Mindfulness Based Stress Reduction, MBSR, Bob Stahl, Health Currents RadioWhat’s in a finger snapping ten times? One moment. As Bob Stahl’s meditation teacher once told him, “Being mindful one moment is better than living one hundred years without being present.”

Sermon delivered by UTUUC member Terry Kinsey on July 13, 2014. Preeding the sermon is a faith testimonial given by Terry's husband, Jay Cohen. Terry Kinsey joined Unity Temple in 1982. As a member of this congregation he has taught many AYS/OWL classes for junior high students. He participates in the original Men's Group which started in 1984 and has led several Men's Retreats. Terry founded Mother Earth Adventures which existed from 1991-2010 and offered vision quests and sweat lodges. In 1985, he became a counselor at Marwood Camp, a weeklong UU rites of passage summer camp for adolescents. Professionally, Terry is a retired pediatric physical therapist. His interest in secular/liberal Buddhism began in 1998. He has attended many 9- to 11-day silent Buddhist wilderness backpacks and canoe retreats as well as many 6- to 11-day silent center-based Buddhist retreats. His Buddhist "coach" is Stephen Schettini. Terry can be reached at terrykinsey@gmail.com. Jay Cohen joined his first Unitarian Church back in 1989. He moved to Oak Park in 1998 and became a Marwood counselor in 1999. He is a full-time professor at a community college and is both a certified public accountant and a licensed clinical social worker. Jay recently completed an 8-week course on Mindfulness-Based Stress Reduction at Rush University. This is a certified course based upon the work of Dr. Jon Kabat-Zinn from the University of Massachusetts Medical Center. Jay and Terry have been together for 19 years and were recently legally married with 10 other couples at Unity Temple's own "Big Fabulous Gay Wedding" on June 8th of 2014.  They have 3 adult children and 4 grandchildren.

Do you have a hard time saying no to others, no matter how outrageous their requests? If so, you might be a chronic people-pleaser. Unfortunately, because we live in a society that praises putting the needs of others before ourselves, it can be difficult to break this bad habit. And while thinking of others is always commendable, there is a fine line between sacrifice and senseless approval seeking. In The Need to Please, a leading mindfulness expert and psychotherapist provides compassionate, mindfulness-based techniques that will help chronic people-pleasers like you address and overcome your fears of failure, inappropriate self-sacrificing, loss of personal identity, and voracious need of approval. In addition, you will learn to put an end to the codependent behaviors that lie at the heart of being a people-pleaser.   Change is hard—especially when it means going against years of social conditioning. But if you’re ready to “Just Say No,” to others’ demands and start saying, “Yes” to your own needs, this book can help.   You can find out more about these mindfulness techniques atlivingmindfully.org.   About the author: Micki Fine, MEd, LPC, is the founder of Mindful Living in Houston, TX and a certified mindfulness teacher. She was awarded this credential from the University of Massachusetts Medical Center, where Jon Kabat-Zinn founded the renowned Center for Mindfulness. She holds a master’s degree in counseling psychology and is licensed as a professional counselor. She has been in private psychotherapy practice since 1990, and currently teaches mindfulness in her private practice, The Jung Center, and Rice University. To find out more about Fine, visit livingmindfully.org.